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ABSTRACT 
 
Programmed cell death 4 (PDCD4) has been described as a tumor suppressor in 
multiple cancer cell types.  In vitro, exogenous expression of PDCD4 results in decreased 
anchorage-independent cell growth and invasion.  These anticancer phenotypes are 
attributed to inhibition of the translation initiation factor eIF4A when bound to PDCD4.  
In this dissertation, I report the discovery of novel interactions with the nuclear pore 
protein Nup153, the exon junction core protein eIF4AIII, and protein arginine 
methyltransferase 5 (PRMT5) that may modulate PDCD4 in a cancer context.    
PDCD4 levels are often suppressed in cancerous cells compared to normal 
surrounding tissues, and elevated expression in tumors is correlated with better survival 
outcomes.  Despite this, 20-30% of patients with tumors that express high levels of 
PDCD4 have poor outcomes, indicating that these cancers deactivate PDCD4.  Our 
analyses of transcript expression in breast cancer patients show that simultaneous 
upregulation of PRMT5 with PDCD4 results in poor survival outcomes.  Using an 
orthotopic tumor model, I demonstrate that simultaneous expression of PDCD4 and 
PRMT5 in the breast cancer cell line MCF7 causes accelerated tumor growth.  This 
tumor growth phenotype is dependent on PRMT5 enzymatic activity and the PDCD4 N-
terminal site that is modified by PRMT5. This demonstrates that PDCD4 tumor 
suppressor function is radically altered when modified by PRMT5.  Furthermore, this 
provides a mechanism for poor outcomes in patients with tumors that express elevated 
iv 
 
PDCD4.  These findings show the utility of tracking both PDCD4 and PRMT5 as 
biomarkers and reveals PRMT5 as a potential target of chemotherapy.         
Finally, PDCD4 acts as a tumor suppressor through inhibition of the RNA 
helicase activity of eIF4A, although the precise mechanism of how this is accomplished 
has been unknown.  In this dissertation, I report that PDCD4 interferes with the ability of 
eIF4A to interact with RNA, thereby deactivating its RNA helicase function.  This 
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1.1 Broad issues in cancer 
Despite significant advances in treatment and detection, cancer is still a leading 
cause of mortality, especially in developed countries.  The American Cancer Society 
estimates that there are 11.6 million people who have had or are actively living with 
cancer in the United States (approximately 1 in 27 people).  It is estimated that 1.5 
million people will be diagnosed and 570,000 will die of the disease in 2010 which is on 
pace for 1,500 mortalities a day (1). 
Unlike pathologies resulting from invasion of external pathogens with dissimilar 
physiology, cancer is a direct descendent of normal cells within the body.  This 
characteristic makes cancer both challenging to differentiate from healthy cells, 
especially in early stages, and difficult to treat because of overlap in expression of targets 
of chemotherapy between normal and tumor cells.  Advances in imaging and new 
diagnostic tests have increased the accuracy of detection of cancer at very early stages.  
This has lead to increased survival of many cancer patients but has also caused new 
dilemmas regarding aggressiveness of treatment and type of treatment.  Historically, for 
instance, breast cancer prognosis has been defined by the tumor-node-metastasis (TNM) 




involvement and metastasis.  This prognostic standard does not account for markers that 
determine aggressiveness, treatment type and treatment sensitivity, especially in 
subclinical cancers detected by early screening (2).   Unknown and/or unquantifiable risk 
assessments based on new detection methods can lead to over treatment of indolent 
disease, exposing patients to unwanted side effects and even new cancers, or under 
treatment of aggressive disease, risking recurrence (3).  An example of this dilemma is a 
stage I-II breast cancer tumor with a negative lymph node biopsy.  The decision to 
commit to adjuvant therapy after surgery and radiation remains difficult when weighing 
the possible side effects of chemotherapy/endocrine therapy versus unknown disease 
recurrence probability (3).   
Increasingly, the molecular signatures of tumors are used to determine both 
outcomes and treatment options and have fueled intensive research into new prognostic 
indicators including microarray, RT-PCR and protein expression based tests.  These tests 
have not only helped in patient risk assessments but have also yielded new targets for 
drug design. Cancer is an extremely diverse set of diseases with many types, and despite 
these new innovations in prognostic indicators and development of new drugs, there are 
numerous cancer types with little recourse.  Expanding the use of new prognostic tools 
and adding new ones to the kit will help inform doctors and patients on treatment type 
and could provide new targets for chemotherapy. 
 
 
1.2 Translation initiation and cancer 
Cancers are defined by a lack of growth control, an ability to escape apoptosis, 




control are overcome in the process of malignant transformation and each one of these 
pathways is of interest for yielding new biomarkers and potential drug targets.  Loss of 
regulation can occur in cell signaling, genomic stability, transcriptional control, transcript 
stability and translation.  In the last few decades, protein translation has become 
increasingly understood as an important point of control, and disregulation, in 
oncogenesis (4, 5).  The defining quality of uncontrolled cell growth is predicated on the 
ability of the cell to upregulate its normal capacity to synthesize building blocks 
necessary for cell division.  Specifically, this node of regulation is at the rate-limiting step 
in the production of proteins, translation initiation, when the ribosome loads onto 
messenger RNA with the help of a protein complex and is accurately positioned at the 
start codon.  Beyond “bulk” levels of translation, growth-related proteins have specific 
translational control mechanisms that can be targets of deregulation.  These include 
sequences targeted by microRNAs and also structures within the 5’ and 3’ untranslated 
regions of growth-related mRNAs that allow for fine tuning of expression beyond 
transcription (5).  Overall, disregulation of translation initiation during oncogenesis is 
now recognized as an important step to malignancy and is garnering broad interest as a 
source of prognostic indicators and targets for chemotherapy. 
The initiation step of so-called “cap-dependent” translation occurs when the 
translation initiation complex eIF4F binds the 5’ methyl cap.  The 5’ cap is a specialized 
structure containing a guanine nucleotide modified by a methyl group at position seven 
and connected to the mRNA strand by a 5’, 5’ triphosphate linkage (i.e. an inverted 
guanine that confers resistance to endonucleases).  Cap-dependent translation makes up 




structures termed internal ribosome binding sites (IRES) is less dependent on the 
components that comprise eIF4F and is a major source of new protein synthesis during 
mitosis of the cell cycle when cap-dependent translation is inhibited (4, 5).   Once loaded 
onto mRNA, the eIF4F complex recruits the 43S initiation complex (which is composed 
of the 40S ribosome, eIF5 and the ternary complex eIF2GTP-tRNAi) then scans the 
5’UTR, unwinding secondary RNA structures that are encountered, until it is positioned 
at the appropriate start AUG codon.  The end of translation initiation is marked by 
hydrolysis of GTP to GDP, causing release of eIF2 and recruitment of the 60S ribosome 
to the 43S initiation complex.  This forms the complete translation-competent 80S 
ribosome and that subsequently catalyzes the first peptide bond with help from eIF5A (4).  
Misregulation of any translation initiation factor is potentially relevant in cancer biology, 
but there is increased interest in the eIF4F complex as many of its components are 
implicated in oncogenesis. 
The critical steps of recognizing the 5’ methyl cap and scanning the 5’UTR is 
carried out by the three proteins that make up the eIF4F complex: eIF4E, eIF4G and 
eIF4A.  eIF4E, the cap binding protein of the eIF4F complex, is overexpressed in 
numerous cancers and its overexpression is known to transform NIH3T3 cells (6).  
Phosphorylation of eIF4E at serine 209 is also associated with some cancers (5).  In 
conjunction with overexpression, specialized inhibiting proteins –4E-binding proteins 
(4E-BPs)– are often deactivated, increasing the effective concentration of eIF4E in cancer 
(7).  4E-BP binds and inhibits association of eIF4E with the 5’ methyl cap and 
incorporation into the eIF4F complex.  The pro-cancer mTOR signal pathway hyper-




eIF4G is a large scaffold protein that links eIF4E with eIF4A and the ribosome 
and additionally recruits kinases responsible for phosphorylation of eIF4E at serine 209.  
eIF4G is expressed in two isoforms, eIF4G1 and 2, with isoform 1 being the most 
common.  eIF4G1 is overexpressed in some cancers, and exogenous upregulation of 
eIF4G1 can transform NIH3T3 cells in the absence of upregulated eIF4E (9-11).  eIF4G 
was found to be highly elevated in inflammatory breast cancer,  in the absence of changes 
in levels or phosphorylation of eIF4E (12).  The ability of eIF4G to transform cells, and 
its upregulation in cancers in the absence of eIF4E upregulation, indicates that eIF4G 
may upregulate cap-independent translation.  Cap-independent translation is mediated by 
special mRNA sequences that form internal ribosome entry sites (IRESs) and this 
specialized form of translation is often dependent on eIF4G (and in some cases eIF4A) 
but not on eIF4E (12).  Despite these later findings, the small molecule inhibitor 4EG1-1 
inhibits eIF4G1 and eIF4E interaction and has tumor killing properties in tissue culture 
(13, 14). 
The last component of the eIF4F complex, eIF4A (or more specifically, the 
paralogues eIF4A1 and eIF4A2), is an ATP-dependent RNA helicase responsible for 
unwinding secondary structures in the 5’UTR of mRNAs thereby allowing efficient 
translation of these transcripts.   eIF4A1 is upregulated in some hepatocellular 
carcinomas and tumor cell lines (15).  The eIF4A small molecule inhibitor, silvestrol, 
blocks translation and also is a potent inhibitor of breast and prostate tumor growth in 
xenograft models (16). 
Interestingly, the tumor suppressor programmed cell death 4 (PDCD4) has been 




status (17-19).  Moreover, the ability of PDCD4 to function as a tumor suppressor in vitro 
appears to be dependent on its ability to bind to eIF4A and inhibit translation (18, 19).    
PDCD4 is down-regulated in a number of cancers and is a prognostic indicator, with 
increased expression correlating with increased survival and lower tumor grade (20-24).   
Many studies place PDCD4 as a central player at the node of translation initiation and 
point to a critical role for PDCD4 levels in the generation/progression of numerous tumor 
types. 
Although translation regulation is a strong theme in many studies centered on 
PDCD4, other functions, including RNA binding and transcriptional control (25, 26) that 
may be independent of translation, have been attributed to PDCD4 and may play a role in 
its tumor suppressor functions.  I will review the major findings in the field to help 
synthesize what is known about PDCD4 function and regulation. 
 
1.3 Discovery of PDCD4 and its role in tumor suppression 
PDCD4 (also termed MA-3, TIS, DUG, and H731) was first described as a 
transcript up-regulated upon apoptotic stimuli in a variety of blood cell lines.  These 
stimuli included ionomycin, phorbol myristate acetate, dexamethasone and removal of 
IL-3 or IL-2 (27).   Notably, exogenous expression of PDCD4 in these same cell lines did 
not induce apoptosis, indicating that PDCD4 is not sufficient for cell death.  PDCD4 is 
expressed in all mouse tissues tested, to varying degrees (27).  Unlike the above reagents 
used to stimulate apoptosis, induction of apoptosis by camptothecin, which blocks 
topoisomerase function, caused downregulation of PDCD4.  This down-regulation was 




resulted in loss of PDCD4 expression at the transcription level (28, 29).  During murine 
embryogenesis, PDCD4 was found to be upregulated although it is unclear what role this 
plays since, later, a knockout mouse of PDCD4 had no visible developmental defects (30, 
31). 
PDCD4 was first connected to cancer in a murine epidermal cell model.  In JB6 
(P+) cells that are sensitive to phorbol ester-induced transformation, PDCD4 was down-
regulated compared to the transformation-resistant JB6 (P-) cell line.  The P- resistant cell 
line became susceptible to transformation when PDCD4 was reduced by anti-sense 
constructs, showing that PDCD4 was necessary for this resistance (32).  PDCD4 was also 
found to confer transformation resistance to the JB6 (P+) cell line (33). Concomitant with 
upregulation of PDCD4 was a down- regulation of AP-1-dependent signaling although 
the mechanism of signal down-regulation was unclear (33). 
Soon after, PDCD4 was discovered to bind the translation initiation protein eIF4A 
(34), blocking its ability to unwind RNA hairpins and decreasing translation of mRNA 
reporters containing structured 5’UTRs (18, 19).  The ability of PDCD4 to block 
transformation in the JB6 mouse model was likewise found to be dependent on binding of 
eIF4A (19).  Furthermore, PDCD4 blocked anchorage-independent cell growth in 
transformed mouse cells (35).  Despite this connection, the molecular mechanism by 








1.4 Clinical and cancer-specific studies of PDCD4 
1.4.1 Skin cancer 
 As stated above, PDCD4 was first recognized as a tumor suppressor in a 
transformed mouse epidermal cell line, when exogenous upregulation of PDCD4 
suppressed the ability of transformed cells to grow in soft agar (35).  Transgenic mice 
overexpressing PDCD4 in the epidermis exhibited a short hair phenotype due to 
shortened anagen (the growth phase of hair follicle) but had no other detectable defect.  
Treatment of the skin of these mice with tumor promoting agents resulted in papilloma 
formation with delayed kinetics and decreased burden compared to wildtype littermates.  
The development of squamous cell carcinoma from papilloma was also significantly 
decreased in these mice, indicating that PDCD4 inhibits both skin tumor development 
and progression in vivo (36).  In a separate study, treating the skin of wild-type mice with 
the linoleic acid metabolite 13-HOA induced upregulation of PDCD4 concurrent with 
inhibition of tumor formation (37). 
In the transgenic mouse model, PDCD4 up-regulation also correlated with down-
regulation of endogenous CDK4 and ODC, both of which are expressed from mRNAs 
with 5’UTRs predicted to have structured hairpins.  This observation reinforced the 
model that translation suppression may be critical to in vivo suppression of 
carcinogenesis (31). 
 
1.4.2 Lung cancer 
 PDCD4 was first studied for clinical relevance in lung cancer.  PDCD4 mRNA 




epithelial cells (HBEC) or in small airway epithelial cells (SAEC) cultured in vitro (20).  
This was confirmed in lung cancer cells compared to surrounding normal cells by 
microarray, where PDCD4 levels were markedly low in higher grade tumors.  To follow 
this up, Chen et al probed a tissue microarray of 248 primary lung cancer samples from 
124 patients for PDCD4 protein.   Eighty three percent of the samples exhibited no 
staining whereas 17% had low nuclear and cytoplasmic staining.  Normal lung tissue 
displayed strong nuclear PDCD4 staining.  The tumors from the tissue microarray were 
further stratified into adenocarcinomas or squamous cell carcinomas.  No correlation was 
made in the squamous cell carcinomas.  Interestingly, PDCD4 was expressed at 
significantly lower levels in higher grade adenocarcinomas whereas no association was 
found with stage, side or nodal status.  The most striking result was that the absence of 
PDCD4 protein expression was significantly correlated with adverse prognosis with a 
mean survival of patients with PDCD4 positive tumors reaching 47 months compared 
with 22 months in patients without expression (20).  This was the first indication that 
PDCD4 was a relevant biomarker for patient outcome. 
 
1.4.3 Colon cancer 
In a study of colon cancer, 71 tumors were compared to 42 adenomas and 71 
normal tissues.  Overall PDCD4 levels assessed by immunohistochemistry showed a 
progressive decrease between normal to adenoma to tumor samples.  Interestingly, 
normal tissue displayed high levels of nuclear PDCD4 whereas the adenomas had 
intermediate and tumors had low levels of staining.   Kaplan-Meier analysis of disease 




of poor outcome.  Notably, transition of PDCD4 from the nucleus to the cytoplasm was 
also correlated with poor outcome (21).  In a separate study of 86 adenocarcinoma and 
carcinoma tissue samples, not linked to patient outcomes, PDCD4 was also observed to 
be down-regulated compared to normal tissue (38). 
In tissue culture models related to colon cancer, overexpression of PDCD4 in the 
colorectal cancer cell line RKO caused a decrease in AP-1 transcription by 
downregulation of the MAPK signal pathway through repression of MAP4K1 expression.  
The overexpression of PDCD4 did not alter the cell’s doubling time in culture but 
inhibited invasiveness of RKO cells by 50-60% in matrigel assays.  This inhibition of 
invasion was attributed to lowered cell migration and loss of expression of matrix 
metallo-proteases (MMPs) (39).  Later, PDCD4 was also found to downregulate u-PAR 
expression at the transcription level by inhibiting the cis-acting transcription factors Sp-1 
and Sp-3 (40).  u-PAR is also involved in breakdown of extracellular matrix and 
contributes to cell invasiveness when expressed.  In a separate study, knockdown of 
PDCD4 in HT29 cells increased invasiveness by 11 fold and induced a fibroblast-like 
morphology of the cells.  This knockdown was accompanied by suppression of E-
cadherin, a molecule that increases cell-cell adhesion, and increases in active nuclear β-
catenin, Tcf4 mediated transcription and AP-1 signaling (38). 
An endogenous micro RNA, miRNA-21, was found to downregulate PDCD4 in 
colorectal cancer tissue culture cells.  Exogenous expression of miRNA-21 caused a 
decrease in PDCD4 and an increase in cell invasion and extravasation using a chicken 
embryo based assay.  miRNA-21 was also found to be expressed in a number of colon 




These tissue culture results help explain, at least in part, the lower probability of 
survival when PDCD4 expression is lost in colon cancer patients.  Tumors with lowered 
PDCD4 levels may have increased mobility due to down regulation of E-cadherin and 
increased invasiveness due to upregulation of u-PAR and MMPs.  These changes, 
together with increased oncogenic signaling through AP-1 and β-catenin, could 
significantly alter cell physiology in a way that results in a more aggressive phenotype 
(higher grade) and increased potential for metastases. 
 
1.4.4 Leukemia and lymphoma 
PDCD4 was first implicated in hematologic malignancies in a knockout mouse 
model (31).  The removal of exon 3 and 4 by targeted homologous recombination 
produced a mouse that lacked mRNA and protein expression of PDCD4.  These mice had 
no gross phenotypic abnormalities such as body weight, temperature or oxygen 
consumption.   Yet, 85% of the Pdcd4 knockout mice developed B-cell lymphoma over 
the course of their life as opposed to 14% for wildtype C57BL/6 littermates.  
Interestingly, these knockout mice also had a reduced incidence of diabetes when induced 
by self-reactive lymphocytes upon treatment with streptozotocin. Further, the severity of 
experimental autoimmune encephalomyelitis induced by treatment with myelin 
oligodendrocyte glycoprotein was also reduced in Pdcd4 knockout mice.  Investigation 
into the cause of lowered immune response revealed that overall translation,  along with 
IL-10, IL-4 and IFN-γ, were all upregulated in isolated cells from the knockout mice 
whereas ~ 50 other immune response molecules/cytokines were unaffected by PDCD4 




lymphomas could be due in part to a dysfunctional immune system due to inappropriate 
expression of these three molecules; it would be of interest to transplant a mix of wild-
type and Pdcd4 knockout hematopoietic cells to evaluate the contribution of cell 
autonomous mechanisms. 
Acute myeloid leukemia is characterized by accumulation of progenitor blood 
cells that are blocked in the ability to differentiate.  Stimulation of these cells to 
differentiate by addition of drugs such as all-trans retinoic acid (ATRA) can be an 
effective treatment with minimal side effects.  Ozpolat et al. found that treatment of the 
acute promyelocytic leukemia cell line NB4 with ATRA causes both differentiation and 
upregulation of PDCD4.  NB4 cells transfected with siRNA to deplete PDCD4 failed to 
differentiate upon ATRA stimulation.  Also, p27kip1 and DAP5 (both necessary for 
differentiation) were down-regulated while c-myc and WT1  (both poor prognostic  
indicators and normally down-regulated by ATRA treatment) were upregulated 
concurrent with siRNA-mediated knockdown of PDCD4 and ATRA treatment.  Both the 
upregulation and downregulation of these proteins were at a posttranslational level as 
mRNA concentrations remained constant indicating that PDCD4 may be directly 
regulating expression by translation inhibition (42). 
The development of B-cell lymphoma in mice lacking PDCD4 strongly indicates 
its role in tumor suppression.  PDCD4 also helps regulate the inflammatory response in 
mice.  The inability of acute myeloid leukemia cells to respond to differentiation signals 
when PDCD4 is missing points to a possible role for PDCD4 in proper blood lineage 
development, although a gross phenotype may only appear under immune cell challenge.  




PDCD4 also increases translation of some mRNAs making it a selective translation 
suppressor and activator. A pro-translation role of PDCD4 is one possible explanation for 
a pro-tumor growth phenotype attributed to PDCD4 that we have discovered (See 
Chapter 3). 
 
1.4.5 Hepatocellular carcinoma 
In a study of 18 samples from patients with hepatocellular carcinoma (HCC), 
PDCD4 protein was found to be down-regulated in tumors compared to adjacent normal 
hepatocytes.  PDCD4 was expressed in the cytoplasm of both normal hepatocytes and 
HCC.  As a follow-up, PDCD4 was transfected into the HCC cell line Hu7. DNA 
fragmentation was found to occur in cells where exogenously expressed PDCD4 
accumulated in the nucleus.  Well-known markers of apoptosis were present in cells 
which expressed PDCD4.  HCC is known to undergo apoptosis with TGF-β1 treatment; 
TGF-β1 treatment of Hu7 cells caused an upregulation of PDCD4 concurrent with 
apoptosis.   Finally, antisense knockdown of PDCD4 caused a loss of apoptosis upon 
TGF-β1 treatment.  These results indicate that PDCD4 is sufficient to induce apoptosis in 
this hepatocellular carcinoma cell line and is necessary for TGF-β1 mediated HCC cell 
death (43).   In contrast, a second study did not report apoptosis in MHCC-97H, MHCC-
97L, or Hep3B HCC cell lines upon exogenous expression of PDCD4 but rather a block 
in matrigel invasion assays was found (44).   Finally, a separate study indicated that 
overexpression of PDCD4 blocks both the upregulation and phosphorylation of eIF4E in 
MHCC-97L cells upon hydrogen peroxide treatment (a treatment known to induce 




translation in these cells and it is unclear what role eIF4E may play in metastasis of HCC.  
Follow up on the ability of PDCD4 to cause apoptosis in one cell line, Hu7, but not in 
others, MHCC-97H and L and Hep3B may provide clues of oncogenic addiction 
pathways in subcohorts of HCC and may also provide a better understanding of PDCD4 
targets. 
In a small study of 68 Chinese men with HCC, smokers and non smokers were 
stratified.  Smokers were found to have significantly less PDCD4 expression in normal 
liver compared with nonsmokers but there was no difference in expression in carcinoma 
tissue in either cohort.  On average, smokers developed HCC 10 years earlier than 
nonsmokers, raising the question of whether loss of PDCD4 in the liver, due to smoking, 
may play a role in early development of HCC (45). 
 
1.4.6 Breast cancer 
A study of 65 breast tumors compared to 15 cases of ductal carcinoma in situ 
(DCIS) and 5 samples of normal breast tissue found that PDCD4 was progressively lost, 
as assessed by immunohistochemistry, from normal to DCIS to ductal carcinoma.  There 
was mixed subcellular localization with a primarily cytoplasmic localization of PDCD4 
in normal breast tissue.  PDCD4 was primarily localized in the cytoplasm in invasive 
ductile carcinoma but was at a much lower level than DCIS or normal tissue.  Also of 
note, PDCD4 nuclear localization strongly correlated with ER+ and HER2/neu+  DCIS 
cells but there was no correlation with retinoic acid receptor or progesterone receptor 
expression (24).   Interestingly, in a previous study from the same lab, culturing RAR+ 




held true in a neuroblastoma and acute myeloid leukemia cell lines also positive for 
RAR+.  Treating ER+, Her2/neu+ cell lines with the estrogen receptor antagonist ICI-
182780, or with Herceptin, also up regulated PDCD4.  This suggests a potentially 
complicated interplay between hormone receptors and HER2/neu signaling and PDCD4 
expression in breast cancer. 
 
1.4.7 Esophageal cancer 
In esophageal cancer, loss of PDCD4 expression correlated with worse tumor 
grade.  Normal tissue expressed nuclear PDCD4, which was down regulated or lost in 
cancerous tissue.  Residual nuclear PDCD4 staining in tumors correlated with longer 
disease free survival and overall survival (46).  This indicates that PDCD4 also is lost in 
the progression of esophageal cancer and that subcellular localization may play an 
important tumor suppressor role. 
 
1.4.8 Ovarian cancer 
In a study of ovarian tissue and tumors, PDCD4 was localized to the nucleus, as 
assessed by immunohistochemistry,  in all normal tissue positive for expression (84% of 
normal samples expressed PDCD4).  Of 44 tumor samples, 18 had PDCD4 expression.  
Of these, 6 expressed PDCD4 in the nucleus, 9 had predominantly cytoplasmic 
expression and 4 had mixed localization.  Clinical follow-up established that high 
PDCD4 expression (those above the median for PDCD4 expression) correlated with 
longer disease free survival but not with age, stages of disease, histological types, grade, 




between protein and mRNA expression of PDCD4 (23).  Overexpression of PDCD4 in 
SKOV3, 3AO, and CAOV3 ovarian cancer cells caused impaired proliferation, 
corresponding to cell cycle arrest at S and G2 phase and apoptosis.  Subcutaneous 
injection of SKOV3 cells engineered to overexpress PDCD4 into nude mice resulted in 
tumors that grew significantly slower than control cells (47).  The mouse model, clinical 
data and cell culture in vitro data all point to a role for PDCD4 inhibiting growth of 
ovarian cancer cells. 
 
1.4.9 Bladder cancer 
One study of multiple cancer types found that PDCD4 was upregulated in bladder 
cancer and breast cancer compared to normal cells using the monoclonal H731 antibody 
raised against partially purified bacterially expressed constructs (48).  This result may 
indicate that PDCD4 is regulated differently in bladder although we know that PDCD4 is 
often down regulated in breast cancer (24) (Chapter 3).  Although a clear result for the 
example provided, use of this H731 antibody for an immunoblot in a separate study 
shows multiple background bands other than PDCD4 and may indicate that the IHC 
results are tracking an alternative marker (32). 
 
1.5 Regulation of PDCD4 
To date, PDCD4 levels are known to be regulated by transcription, protein 
degradation, and miRNA targeting of mRNA.  PDCD4 was originally defined as a 
transcript down regulated by topoisomerase inhibitor treatments and elements within the 




was subject to DNA methylation and gene silencing in glioma (49), however, treatment 
of breast cancer cells with DNA methyltransferase inhibitors did not affect expression 
levels (24).   
While gene silencing at this locus needs more thorough and critical assessment, 
different mechanisms may well be in play in different cancer types.  A counterintuitive 
observation of PDCD4 regulation is its transcriptional upregulation by v-Myb (an 
oncogenic viral homologue of c-Myb), found in cultured chicken cells (50, 51).  The 
significance of this regulation is unclear in light of not knowing if avian and human 
PDCD4 differ in function and regulation.  Dorello et al. elegantly demonstrated that 
PDCD4 is a target for proteasomal degradation through activation of the mTOR pathway.  
This occurs following mitogen stimulation, subsequent phosphorylation of PDCD4 by 
S6K1, and ubiquitination catalyzed by β-TRCP (52). This proteasomal degradation 
pathway was also activated by treatment of cells with phorbol esters (53) and through 
BCR-ABL fusion oncogenic protein signaling (54).  The oncogenic micro RNA, miR-21, 
was found to target PDCD4 mRNA, leading to a block in translation and transcript 
degradation (41, 55).  miR-21 regulation of PDCD4 has been found in breast cancer, 
hepatocellular carcinoma, and colon cancer  and may regulate PDCD4 across numerous 
other cancers (41, 55-58).  Recently, PDCD4 was also found to be a target of miR-183 in 
hepatocellular carcinoma indicating that other micro RNAs also downregulate PDCD4 
(59). In a study of PDCD4 mRNA levels and protein expression in 14 squamous cell 
carcinomas (SSC), there was little correlation between mRNA levels and PDCD4 
expression (60).  This highlights that PDCD4 levels can be regulated independent of 




Subcellular localization may also regulate PDCD4 activity.  High efficiency 
translation occurs when polyribosomes are loaded onto mRNAs in cytoplasm and the 
activity of PDCD4 as a translation inhibitor is thought to also occur in this subcellular 
compartment (19).  In mouse skin and human breast tissue, PDCD4 is localized primarily 
to the cytoplasm (24, 36).  Yet, PDCD4 is prevalent in the nucleus in healthy lung and 
colon cancer cells and is cytoplasmic in the corresponding cancers (20, 21, 61).   In 
chicken cells, PDCD4 shuttles between the nucleus and the cytoplasm and has been 
shown to contain a putative nuclear localization signal (25).  If PDCD4 functions as a 
tumor suppressor in the cytoplasm, sequestration of PDCD4 in the nucleus would 
effectively deactivate this function.  Alternatively, the pioneer round of translation occurs 
in or en route from the nucleus and could be a target of PDCD4 activity that leads to 
tumor suppression (see Chapter 2).  PDCD4 has also been reported to directly alter 
transcription leading to growth suppression and drug sensitivity in prostate cancer cells 
(26). Cytoplasmic localization would alter this function.  It remains unclear where 
PDCD4 exerts its major tumor suppressor function and what role subcellular localization 
plays.  Experiments testing the ability of PDCD4 to inhibit anchorage independent cell 
growth or matrigel invasion when trapped in the cytoplasm or nucleus may help clarify if 









1.6 Roles of PDCD4 downstream of/or alternative  
to translation regulation 
1.6.1 Cell growth/cell cycle 
In many cell lines, overexpression of PDCD4 does not affect doubling times 
under normal tissue culture conditions (18, 19, 27, 35, 36, 39, 40).  In an endocrine tumor 
cell line, Bon-1, transfection of rat PDCD4 caused an inhibition of cell growth.  This was 
initially presumed to be through down-regulation of carbonic anhydrase type II at a 
posttranscriptional level.  In a later study, however, p21waf1/cip1 was found to be 
upregulated following overexpresison of PDCD4 in these cells, providing an alternative 
explanation for slower cell proliferation, as p21 inhibits the transition from G2 to M 
phase (61, 62).  The reported links between PDCD4 and cell cycle regulators have been 
variable, perhaps due to cell type differences.  For instance, stable knockdown of PDCD4 
via siRNA in HeLa and HT116 cells upregulated  p21waf1/cip1  and no change in cell cycle 
timing was reported  (63).  In a glioblastoma cell line (T98G) starved for 72 hrs and then 
reactivated with serum,  overexpression of degradation-resistant  PDCD4 caused a delay 
in G1/S phase transition, with slower accumulation of cyclin D1, cyclin A, SKP2 and 
slower degradation of p27 (52).    Overexpression of PDCD4 in MHCC-97H HCC cells 
caused a slower growth rate in culture and an accumulation of G1 and G2 phase with a 
reduction in S phase (44).  Expresssion of PDCD4 in the prostate cancer cell line PC3 
also inhibited proliferation in culture but was not analyzed for cell cycle arrest or 
apoptosis (26).  PDCD4 was shown to down-regulate proliferation of ovarian cancer cell 
lines in culture, trapping them in S and G2 phase (47).  It appears that the effects of 




take into account in any experimental design; at the least, doubling times in culture 
should be tested in any experiment where levels of PDCD4 is altered in order to interpret 
changes in tumor growth of the same cells (i.e., is a decrease in tumor growth when 




The ability of PDCD4 to directly cause apoptosis is also variable between studies.  
PDCD4 overexpression has been reported to cause apoptosis in MCF-7, MB-MDA-231 
and T-47D breast cancer cells (reported up to 80%) (64) and in the Hu7 hepatocellular 
carcinoma cell line (43).  But, overexpression of PDCD4 in MCF-7 and MB-MDA-231 
cells was performed by Zhu et al. without any comment on induction of apoptosis.   
Although apoptosis was not directly tested, induction of cell death (especially at 80% 
frequency) would have significantly altered the interpretation of their conclusions and 
would have been difficult to miss if present (65).  Interestingly, unlike in Hu7 HCC,  
overexpression of PDCD4 in  MHCC-97H, MHCC-97L and Hep3G HCC cells did not 
cause apoptosis (44).  This indicates that the direct induction of apoptosis by PDCD4 is 
not only variable between cell types but also cell lines of the same cancer.  This may 








1.6.3 RNA binding 
PDCD4 has been shown to bind RNA in chicken cells in vitro (25) and I have 
demonstrated that human PDCD4 also binds RNA (see Chapter 4).  This function is 
not clearly understood but may play a role in positioning PDCD4 at the site of 
translation initiation.  Alternatively, PDCD4 RNA interactions may play a secondary, 
unknown role in cancer biology.  I show that PDCD4 RNA interactions are altered 
when PDCD4 is bound to eIF4A (Chapter 4).  The role of RNA binding in PDCD4 
tumor suppression or other unknown functions would be an interesting line of 
research to pursue. 
 
1.7 Conclusions and unanswered questions 
Clearly, PDCD4 plays an important tumor suppressor role in surrogate in vitro 
cell assays, such as invasion and migration experiments.  These results are supported by 
clinical data through repeated correlations of low expression of PDCD4 with higher 
tumor grade and poor outcomes.  Despite these findings, it is difficult to clearly 
distinguish which functions attributed to PDCD4 in vitro play a role in cancer etiology 
and progression since in vivo models to test these functions directly have not been used.  
One exception is a study using ovarian cancer cells, although this experiment was not an 
orthotopic tumor model and the cell line in question displayed decreased proliferation in 
culture.  A decrease of tissue culture growth is an in vitro feature (then recapitulated in 
the xenograft model) and does not seem to be a generalizable affect of PDCD4 in cancers 
of other origins (47).  In numerous other cases, however, alterations caused by PDCD4 




tested in parallel with tumor growth or metastasis potential in vivo.  This has left a large 
gap in our understanding of the fundamental role for PDCD4 in modulating tumor 
behavior.  Moreover, the ability of PDCD4 to change the phenotypes of cultured cells 
may be significantly altered by a tissue microenvironment.  This is particularly pertinent 
in breast cancer cells where PDCD4 levels are potentially regulated by hormone receptors 
and growth factor receptors.  This is also a factor in blood cancers because PDCD4 
expression may alter the extracellular cytokine milieu, changing the immune response to 
these cells.  Finally, a major unaddressed question in this field is what accounts for poor 
clinical outcomes when tumors in fact do express PDCD4.  Although 70-75% of patients 
with elevated PDCD4 levels have better prognosis and/or survival, the other 35% of 
patients with elevated levels of PDCD4 fair poorly.  If we understood this discrepancy 
between the presence of a tumor suppressor and poor outcome, we could improve what is 
already a promising biomarker and potentially find ways to unmask the activity of 
PDCD4 in these tumors.  This question ultimately became the central topic of my thesis 
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Interactions between molecules maintain cell homeostasis and are aberrantly 
regulated in disease states.  The protein PDCD4 is a tumor suppressor that is often down-
regulated in a variety of cancers.  The underlying mechanism of PDCD4 tumor 
suppression is thought to occur through blocking the efficient translation of mRNAs with 
structured elements in the 5’ UTR by binding the translation initiation factor eIF4A.  
Loss of PDCD4 in cancer deregulates translational control and would modulate functions 
of other potential binding partners.  Here I describe the discovery of new PDCD4 
interacting partners eIF4AIII, Nup153, and PRMT5, which may also play a part in 




Interactions between biomolecules control cellular homeostasis and are disrupted 
in disease.  Oncogenesis often manifests when genes are mutated or epigenetically 
silenced.  The physiological cell phenomena accompanying these changes, however, such 
as uncontrolled growth and tissue invasion, are a direct result of gains or losses of 




to detect these interactions and the post-translational modifications that control their 
function (1).  High throughput proteomic endeavors have been instrumental in 
determining networks of interactions involved in normal cell homeostasis and in disease 
development (1, 2).  Small-scale protein/protein interaction studies using candidate 
approaches have also yielded valuable information on new disease pathways and are also 
necessary to confirm or inform experimental findings from large-scale analysis (3).  
Directed experiments detecting the network of protein/protein interactions of factors 
known to have oncogenic or tumor suppressor functions could be particularly useful in 
finding new drug targets or better prognostic indicators.    
PDCD4 is a tumor suppressor that binds to eIF4A, disrupting the ability of eIF4A 
to interact with RNA and function in translation initiation (4)  (Chapter 4).  This results in 
inefficient translation of mRNAs that are dependent on eIF4A RNA helicase activity and 
is thought to be the mechanism of PDCD4 tumor suppressor function (5).   In lung, colon, 
ovarian cancer, and esophageal cancer, the presence of PDCD4 is associated with better 
survival outcomes (6-10).  Nevertheless, subpopulations of patients with high levels of 
PDCD4 expressed in tumors have poor survival outcomes, indicating the possibility of 
protein partners that negatively regulate PDCD4 tumor suppressor function.  
Alternatively, the patient population with high tumor levels of PDCD4 and extended 
survival outcomes may have interacting partners that enhance PDCD4 tumor suppressor 
function.   
  Interestingly, PDCD4 also exhibits features, such as nuclear localization and 
RNA binding, that hint at unknown functions, separate from translation regulation, that 




part of understanding the function of proteins, I chose to look for novel PDCD4 binding 
proteins that might illuminate alternative roles in tumor biology.  Three approaches were 
used. The first was a candidate approach based on similarity to known PDCD4 binding 
partner eIF4A.  The second was determining interactions of nuclear pore proteins found 
through a yeast-two-hybrid screen.  Lastly, I looked at differential binding partners of 
PDCD4 in interphase versus mitotic cell cycle based on the known function of PDCD4 as 
a growth/cell cycle regulation molecule.  
 
 
2.3 Experimental Procedures 
2.3.1 Constructs and mutations 
The open reading frame for human PDCD4 was purchased from Open 
Biosystems.  eIF4AII and eIF4AIII were cloned out of a human cDNA library.  All three 
constructs were PCR amplified using Gateway compatible primers and introduced into 
DONR-221 or DONR-321 vectors by BP reactions.  eIF4AIII proline 67 was mutated to 
leucine by site directed mutagenesis.  pGEX4T was converted to a Gateway compatible 
vector (pDEST-pGEX4T) using RFB primers (Invitrogen) and  PDCD4, eIF4AII and 
eIF4AIII were all introduced into this vector by LR reactions.  For bacterial His-tagged 
protein expression, constructs were introduced into pEXP1-DEST vector by LR 
reactions.  For mammalian expression of V5-tagged proteins, eIF4AIII was introduced 







2.3.2 Recombinant protein expression and purification 
GST-tagged PDCD4, eIF4AII, eIF4AIII and eIF4AIIIP67L were expressed as 
follows:  Colonies were picked from agar plates of BL21/RIL cells transduced with GST 
recombinant constructs and spiked into 50 ml, 50 µg/ml Amp, LB broth.  Overnight broth 
cultures were spiked into 700 ml, 50 µg/ml Amp, NZY media.  Cultures were grown until 
they reached an OD600 of 0.8.   GST-recombinant proteins were induced with 0.1 mM 
IPTG for 4 hrs at 22°C.   The cultures were pelleted by centrifugation 5,000 x g 15 
minutes at 4°C. The resulting pellets were resuspended in 10 ml chilled STE buffer (10 
mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA) and re-pelleted by centrifugation as 
before. These pellets were frozen overnight at -80°C and thawed on ice the following day 
and resuspended in 20 ml, 1 x PBS, 2ug/ml leupeptin and aprotinin, 400 µM  PMS and  
0.04 to 0.1% deoxycholate.  Lysates were prepared by sonicating pellets with three bursts 
of 30 seconds apiece on ice.  Lysates were clarified by centrifugation 10,000 x g for 20 
minutes at 4°C.  3 ml of 80% glutathione bead slurry (GE-healthcare) were equilibrated 
in PBS and were added to the clarified supernatants and incubated 2 hours at 4°C to 
conjugate GST proteins to glutathione beads. These beads bound with GST-proteins were 
washed five times with 10 ml of TBS.  To elute GST proteins from glutathione beads, 10 
ml elution buffer (100 mM Tris pH 8.0, 120 mM NaCl, 20 mM glutathioine) was added 
to each sample and incubated for 15 minutes at room temperature.  The eluted beads were 
pelleted by low speed centrifugation 1 minute and the supernatant containing GST-
proteins were concentrated in a Millipore 10,000 MWC concentrator to 1 ml by 
centrifugation at 2,000 x g for 70 min at 4°C.  9 ml of RNAse free TBS was added to 




total of three times to exchange the elution buffer for TBS.   The proteins were finally 
concentrated to 500-300 µl and 10% glycerol was added.  This final protein concentration 
was aliquoted and stored at -80°C.    
Expression and purification of His-recombinant proteins PDCD4 and tandem-
GFP (2 x GFP) was performed as follows: Colonies were picked agar plates containing 
BL21/RIL colonies transduced with His-recombinant constructs.  These isolates were 
spiked into 50 ml, 50 µg/ml Amp, LB broth and grown overnight at 37°C.  Overnight 
liquid cultures were then spiked into 700 ml, 50 µg/ml Amp, NZY media.  Cultures were 
grown until they reached an OD600 of 0.8 (2-4 hours a 37°C).  Recombinant protein 
expression was induced three hours at 37°C with 1 mM IPTG.  Induced bacteria was 
pelleted 5,000 x g for 7 minutes at 4°C and subsequently resuspended in 10 ml of native 
lysis buffer (500 mM NaCl, 5 mM imidizole, 20 mM TrisCl, pH 8.0  4 µg/ml leupeptin 
and aprotinin, 400 µM  PMSF and 0.04% deoxycholate and 1 µg/ml lysozyme).  
Resuspended bacteria were lysed on ice by sonication for 3 bursts lasting 30 seconds 
apiece.  Lysates were clarified by centrifugation at 10,000 x g for 20 minutes at 4°C.   
Three ml of Ni-NTA beads (Novagen) were equilibrated in native lysis buffer and added 
to clarified lysates.  His-recombinant proteins were bound to the Ni-NTA beads 1.5 hours 
at room temperature.   Protein bound beads were washed five times in 10 ml of Native 
Wash Buffer (500 mM NaCl, 10 mM tris-pH 8.0, 20 mM imidazole) 10 minutes per 
wash.  The His-tagged proteins were eluted from the Ni-NTA beads by incubation in 10 
ml of Native Elution Buffer (500 mM NaCl, 250 mM imidazole,  10 mM EDTA, 20 mM 
Tris pH 8.0) for 15 minutes at room temperature.  The elution buffer was replaced by 




centrifuging at 2,000 x g 1.5 hours at 4°C to 1 ml and adding back 9 ml freezer storage 
buffer (500 mM NaCl, 20 mM Tris-cl pH 8.0, 5% glycerol).   I repeated replacement 
three times.  The sample was finally concentrated to 500-300 µl final volume.  The 
concentrated proteins were aliquoted and stored at -80°C.  
  
2.3.3 Purified recombinant GST-eIF4A interaction with  
purified His-PDCD4 protein 
One µg of GST-protein (GST-eIF4AII, GST-eIF4AIII or GST-eIF4AIIIP67L) and 
His-protein were incubated with 20 µl of equilibrated glutathione beads (GE Healthcare) 
per reaction for 2 hours at 4°C in 300 µl of total binding buffer (20 mM HEPES pH 7.6, 
100 mM KCl, 0.5 mM EDTA, 20% glycerol, 0.5 TX-100, 10 µg/ml leupeptin and 
aprotinin and 400 µM PMSF).  The protein bound beads were washed three times in 1 ml 
binding buffer (inverted tube 10 times/wash) to remove any residual binding proteins.  To 
elute protein complexes from the beads, the samples were resuspended in 100 µl of 
sample buffer and heated 3-10 minutes at 98°C.  Twenty µl of each reaction was loaded 
per well on a 10% acrylamide gel and proteins were separated by PAGE.  For controls, 
0.05 µg of each protein was loaded.  To visualize proteins, 2 µl of each reaction were 
loaded per well and detected by anti-GST or penta-His immunoblot or membranes were 
stained with Coomassie.   
 
2.3.4 GST-PDCD4 interactions with exogenously expressed V5-eIF4A 
V5-constructs V5-eIF4AII, V5-eIF4AIII and V5-eIF4AIIIP67L were transfected 




recommendations.  Cells were harvested 16 hours after transfection into 1 ml binding 
buffer (20 mM HEPES pH 7.6, 100 mM KCl, 0.5 mM EDTA, 0.25% Triton X-100, 20% 
glycerol, 2 µg/µl aprotinin and leupeptin, 400 µM PMSF)  per 10 cm dish and dounced to 
lyse.  Lysates were clarified by centrifugation at 20,000 x g for 30 minutes at 4°C.  
Clarified lysates were assayed for protein concentration by Bradford and 65 µg of each 
lysate was diluted in 200 µl of binding buffer.  One µg of GST-PDCD4 or GST bound to 
glutathione beads (GE Healthcare) was added to the diluted lysates and incubated 1 hour 
at room temperature.  Beads with bound proteins were washed three times in binding 
buffer and interacting protein complexes were eluted with sample buffer at 98°C for 3 
minutes.  Samples were loaded onto a 10% acrylamide gel and proteins were separated 
by PAGE.  Immunoblots were probed for V5-eIF4AII, V5-eIF4AIII and V5-eIF4AIIIP67L 
with monoclonal antibody against V5.  Immunoblots were stained with Coomassie to 
visualize GST-PDCD4 and GST proteins.   
 
2.3.5 GST-eIF4AIII and GST-eIF4AII interactions with  
endogenous PDCD4 
HEK293 lysates were prepared by pipetting cells from a 10 cm dish into 1 ml 
buffer. Cells were harvested into either Buffer A (20 mM HEPES pH 7.6, 100 mM KCl, 
0.5 mM EDTA, 0.25% Triton X-100, 20% glycerol, 1 x protease inhibitor (Roche)) or 
Buffer B which was the same as Buffer A but with 0.1% Triton X-100.  Cells were 
briefly spun in low speed bench top microfuge in 1.7 ml tubes and dounced with micro 
douncer.  Lysates were further processed by passing through a 27.5 gauge needle. Lysates 




lysate were brought up to 200 µl with either buffer A or buffer B.  Four µg of GST 
proteins bound to 15 µl of glutathione beads equilibrated in Buffer A or Buffer B were 
added to diluted lysates and incubated 2 hours at room temperature.  Protein complexes 
bound to glutathione beads were washed three times with appropriate buffer A or B.  
These complexes were eluted at 98°C, 3 minutes in sample buffer.   Fifty percent of each 
reaction (the equivalent of 25 µl of lysate) was loaded on a 10% acrylamide gel and 
proteins were separated by PAGE.  2.5 µl lysate was loaded for input.  
 
2.3.6 Interphase and Ultra-S Xenopus egg extract preparation 
Eggs were collected from frogs primed with injection of gonadotropin 15 hours 
prior to harvest.  Eggs were dejellied in 2% cystein for 5 minutes.  Eggs were washed 
three times in 0.25 x Modified Ringer’s Solution (MMR) and one time in 1 x MMR (100 
mM NaCl, 2 mM KCl, 1 mM MgSO4, 2.5 mM CaCl2, 0.5 mM HEPES pH 7.8, 0.8 mM 
EDTA).  Eggs were rinsed two times in egg lysis buffer (ELB) (2.5 mM MgCl2, 500 mM 
KCl, 100 mM HEPES pH 7.6, 250 mM sucrose) and once in ELB with 1 mM DTT and 
0.5 mg/ml CHX.  Washed eggs were packed into tubes by centrifugation 15 seconds at 
800 RPMs in the clinical bench top centrifuge.  Aprotinin, leupeptin and cytochalasin B 
were added on top of eggs at 5 µg/ml.  Eggs were lysed by centrifugation at 10,000 RPM 
15 minutes at 4°C in Beckman JS 13.1 rotor.  Crude lysate was collected (S fraction) 
using an 18 gauge needle and glycerol was added to a concentration of 5%.  Sixty µl 
aliquots were flash frozn in liquid nitrogen and stored at -80°C.     
   Ultra-S egg extract was prepared the same as interphase extract accept that the   




at 4°C.  The resulting supernatant was further centrifuged at 250,000 x g for 25 minutes 
at 4°C.  The supernatant was aliquoted and flash frozen in liquid nitrogen and stored at      
-80°C.   
 
2.3.7 Mitotic Xenopus egg extract preparation 
Preparation of mitotic egg extract was performed like interphase egg extracts with 
the exception of using Mitotic Buffer (240 mM β-glycerophophate pH 7.3, 60 mM EGTA 
pH 8.0, 45 mM MgCl2, 100 µM DTT-final pH 7.3) in place of ELB.   
  
2.3.8 CSF Xenopus egg extract preparation 
Preparation of CSF egg extract was performed like interphase egg extracts except  
after 0.25 x MMR wash, eggs were washed three times in fresh XB buffer (50 mM 
sucrose, 100 mM KCl, 0.1 mM CaCl2, 1 mM MgCl2, 10mM HEPES, pH 7.7).  This was 
followed by three washes of XB buffer containing 5 mM EGTA and an additional 1 mM 
MgCl2. Eggs were packed and lysed in this last XB buffer and the protocol was followed 
as in interphase egg extract preparation.      
 
2.3.9 GST-eIF4AIII interaction with PDCD4 from nocodazole  
treated and serum starved HeLa cells 
HeLa cells were treated with 100 ng/ml nocodazole for 15 hrs or deprived of 
serum for 72 hours.  Lysates were prepared using Buffer A as in step 2.3.5.  Sixty-four µg 
of each lysate were added to 5 µg of GST-eIF4AIII, GST-eIF4AII or GST bound to 15 µl 




hour at room temperature and washed three times in binding buffer.  Reactions were run 
on 10% acrylamide gels and proteins were separated by PAGE.  Lysate equivalent to 
10% of reactions were loaded in input lane. PDCD4 was probed by immunoblotting 
(antibody 51495 from AbCam at 1:1000).  GST-proteins were visualized by subsequent 
Coomassie staining of immunoblot.      
 
2.3.10 GST-PDCD4 binding reaction in Ultra-S egg extracts 
Fifty µg of GST-PDCD4 or GST were bound to 20 µl of glutathione beads 
equilibrated in binding buffer (50 mM HEPES pH 7.8, 200 mM NaCl, 5 mM MgCl2, 
0.05% Triton X-100, 2 µg/ml leupeptin and aprotinin, 400 µM PMSF) by incubating 
together 1 hour at room temperature in 200 µl of binding buffer.  GST-protein bound 
beads were washed three times with 1 ml binding buffer.  Fifty µl of Ultra-S were added 
to each bead pellet and brought up to 200 µl with binding buffer.  GST-proteins were 
incubated with Ultra-S at room temperature 2 hours.  Protein complexes were washed in 
binding buffer four times.  Protein complexes were eluted from the glutathione beads in 
20 µl sample buffer at 98°C for 3 minutes.  Fifty percent of each reaction was loaded on a 
6% acrylamide gel and proteins were separated by PAGE.  In the input lane, 0.2 µl of 
Ultra-S was loaded.  Immunoblots were probed for Nup214, Nup153, Nup62, Nup98, β-
COP or Tubulin.  A separate gel was loaded with 1 µg or GST-PDCD4 and GST as a 
loading control and Coomassie stained.      






2.3.11 GST-PDCD4 interacting proteins in mitotic and interphase  
egg extract for mass spectrometry analysis 
Fifty µg of GST-PDCD4 or GST were incubated with 20 µl of glutathione beads 
(GE Healthcare) 1 hour in 500 µl of binding buffer (50 mM HEPES pH 7.5, 200 mM 
NaCl, 5 mM MgCl2, 0.5% Triton X-100). Beads were washed three times in binding 
buffer.  To the beads, 100 µl of mitotic or interphase egg extracts were added with an 
additional 400 µl of binding buffer.  The protein bound beads were incubated with egg 
extract for 1.5 hour at room temperature.  Samples were washed briefly two times with 
500 µl of binding buffer.  Beads were resuspended in 40 µl sample buffer and heated 
98°C for 3 minutes to elute protein complexes.  All 40 µl of each sample were loaded 
onto a 12% acrylamide gel and separated by electrophoresis.  The resulting gel was 
subsequently stained with Coomassie to visualize interacting proteins. A 72 kD band in 
the interaphase extract lane and a 30 kD band in the mitotic lane were excised and sent 
for mass spectrometry analysis.  All buffers were made with new reagents and fresh 
nano-water.  Gel boxes and tubes used for samples were washed three times in methanol 
and then three times with nano-water before use to prevent environmental contamination. 
Gloves were used at all times.       
 
2.3.12 GST-PDCD4 interactions in CSF and interphase egg extract 
 supplemented with cyclinB 
Twenty-five µg of GST-PDCD4 or GST were bound to 20 µl of glutathione beads 
(GE Healthcare) 1 hour at room temperature in 200 µl of binding buffer (50 mM HEPES 




was cycled into a mitosis state by adding Cyclin B and Creatine Kinase,  
Phosphocreatine, and  ATP and incubating for 75 minutes at room temperature.  To each 
20 µl of protein bound beads, 60 µl of either interphase extract, interphase extract with 
cyclinB, mitotic extract or two preparations of CSF extract with or without phosphatase 
inhibitors (phosphatase inhibitors: 4 mM imidizole, 50 mM NaF, 2 mM 
NaOrthovanadate, 20 mM NaPyrophosphate, 10 mM β-glycerolphosphate) were added.  
Extracts were incubated with GST proteins 1.5 hours at room temperature.  Complexes 
were eluted at 98°C for 3 minutes in sample buffer and run on 12% acrylimide gels.  
PRMT5 and Nup214 and Nup153 were assessed by immunoblot.  GST protein capture 
was assessed by subsequent staining of the immunoblot.   
     
2.3.13 In-gel protein digestion and mass-spectrometry 
An SDS-PAGE gel slice with the band of interest was destained in 50% methanol, 
sliced into small pieces, and then dehydrated in acetonitrile. Samples were taken to our 
core facility and analyzed as follows: TPCK-modified trypsin (Promega ; 20µl of 10ng/µl 
in 50 mM ammonium bicarbonate) was added to the gel pieces and incubated for 2 to 4 
hours at 37ºC. LC/MS/MS analysis was then performed using a LTQ-FT hybrid mass 
spectrometer (ThermoElectron Corp). Primary mass spectra were acquired with the FT-
ICR; MS/MS fragmentation spectra were acquired in the ion trap. Digested samples were 
introduced by nanoLC (2D-Ultra, Eksigent, Inc.) with nano-electrospray ionization 
(ThermoElectron Corp). NanoLC chromatography was performed using a homemade 
C18 nanobore column (75 um ID x 10 cm; Atlantis C18, 3 um particle (C18 material 




acetonitrile (with 0.1% formic acid) to 60% acetonitrile (with 0.1% formic acid) with a 
flow rate of 350 nl/min. Peptide molecular masses were measured by FT-ICR yielding 
primary mass spectra of peptides with mass errors less than 2 ppm. Peptide sequencing 
was performed by collision-induced dissociation (CID) in the linear ion trap, yielding 
fragment ions with mass errors typically less than 0.2 Da. All identified peptides from 
protein digests were assigned from protein database searches, using in-house processing 
with MASCOT search engine (in-house licensed, ver. 2.2.1, Matrix Science, Inc.).  
 
2.3.14 Nocodazole treatment and GST-PDCD4 pull-down 
HEK293 and HT29 cells were cultured in DMEM supplemented with 10% FBS.  
HEK293 and HT29 cells were treated with Nocodazole at 100 ng/ml for 17 hours.  Cells 
were harvested by using a tissue scraper with egg extract binding buffer (EEBB) (20 mM 
Hepes pH 7.6, 200 mM NaCl, 5 mM MgCl2, 0.5% Triton X-100, 2 µg/ml leupeptin and 
aprotainin and 400 µM PMSF) and dounced to lyse cells.  Lysates were centrifuged 
20,000  x g for 30 minutes at 4°C to pellet insoluble debris.   In each binding reaction, 
400 µg of supernatant were used along with 25 µg of GST-PDCD4 or GST bound to 
glutathione beads.  Samples were incubated at room temperature 2 hours rotating.  Beads 
were washed three times with 500 µl of EEBB and proteins were eluted with SDS-sample 
buffer 2 minutes at 95°C.  Reactions were run on a 10% acrylamide SDS gels and 








PDCD4 and PRMT5 antibodies were acquired from Abcam. For immunoblots, α-
PDCD4 antibody was used at 1:1000-2000 while α-PRMT5 antibody was used at 1:1000. 
Lysates were loaded between 2-10 µg for immunoblots.   Anti-V5 antibody (2F11F7 
Invitrogen) was used at 1:1000, anti-tubulin (YL1/2, Accurate chemical and Scientific 
Corp.) at 1:2000 and anti-β-COP (Affinity Bioreagents) at 1:2000 for immunoblots. 414 
antibody (Covance) was used at 1:1000 and phospho-H3 antibody (Millipore) was used at 
1:1000. Anti-penta-His (Invitrogen) antibody was used at 1:2000.  Rabbit anti-GST 
antisera was prepared in our lab and used at a concentration of 1:5000. 
  
2.4 Results  
2.4.1 Recombinant PDCD4 interacts with eIF4AIII produced recombinantly  
but not derived from a mammalian cell lysates  
PDCD4 is involved in translation regulation by interacting with the translation 
initiation factors eIF4AI and II, interfering with their RNA helicase function (4).  eIF4AI 
and eIF4AII are differentially expressed in various tissues, with eIF4AII highly expressed 
in the liver and brain (12).   eIF4AI and II, which are 89% identical, are functionally 
interchangeable molecules and are often referred to collectively as eIF4A (13).  The 
ability of PDCD4 to block eIF4A helicase function is thought to occur primarily in the 
cytoplasm (4), although PDCD4 is localized primarily in the nucleus in many cells (6, 8, 
9).  A closely related protein to eIF4AI and II, eIF4AIII, is an integral core molecule of 
the exon junction complex (EJC) and is found primarily in the nucleus (14, 15).   The 




complex promotes efficient transport of mRNAs from the nucleus to the cytoplasm (16, 
17) and can impact downstream fates of mRNA, such as translation efficiency, 
localization and stability (18-20).  For instance, persistence of the EJC on mis-spliced 
RNAs targets these species for degradation, termed nonsense mediated decay (21).  
Alignment of eIF4A to eIF4AIII shows 72% identity over a 378 residue overlap (Figure 
2.1).  The regions surrounding residues known to be involved in PDCD4 binding are 
conserved (Figure 2.1 regions in yellow).  Although PDCD4 interaction with eIF4AI and 
eIF4AII (eIF4A) has been extensively studied, a novel interaction with eIF4AIII has not 
been explored.  This interaction could alter known functions of the EJC: changing the 
ratio of nuclear and cytoplasmic mRNAs, exon utilization and the efficiency of 
translation or nonsense mediated decay, any of which might contribute to suppression of 
cell growth and transformation.   Since eIF4AIII is closely related to the known PDCD4 
binding partners eIF4AI and eIF4AII and both PDCD4 and eIF4AIII are localized in the 
nucleus of human cells, we hypothesized that PDCD4 could also interact with eIF4AIII 
and that this interaction could contribute in a novel way to the tumor suppressor function 
of PDCD4. 
To determine if PDCD4 and eIF4AIII directly interact, both molecules were 
bacterially expressed as recombinant proteins.  Glutathione-S-Transferase (GST)-tagged 
eIF4AIII and GST-tagged eIF4AII were incubated with His-tagged PDCD4.  Glutathione 
resin capture of GST-eIF4AIII or GST-eIF4AII also co-isolated His-PDCD4 from the 
protein mixture (Figure 2.2, lane 1), whereas GST alone did not (Figure 2.2, lane 7).  To 
further determine the specificity of this interaction, we mutated eIF4AIII at proline 67 to 




loss of PDCD4 binding (22).  When this eIF4AIII mutant was expressed as a recombinant 
protein, it displayed reduced binding to PDCD4 (Figure 2.2, lane 3).  In this and other 
experiments, wild-type eIF4AIII had reduced binding compared to the positive wild-type 
eIF4AII control (Figure 2.2, lane 5 compare to lane 1).   Overall, these results 
demonstrate that eIF4AIII can also directly interact with PDCD4 and that the proline 
analogous to that in the known binding partner eIF4AII is necessary for interaction with 
eIF4AIII.  Despite the high similarity between protein sequences, eIF4AIII appears to 
have a lower affinity for PDCD4 than eIF4AII.  This could be a result of the divergent 
sequence in other amino acids necessary for binding or it could be due to allosteric 
hindrance.        
In this in vitro protein/protein binding assay, neither PDCD4 nor eIF4AIII contain 
native cellular interacting partners or post-translational modifications.  To further 
characterize the PDCD4/eIF4AIII interaction I chose to isolate transfected V5-eIF4AIII 
and V5-eIF4AIIIP67L from cell lysates using recombinant purified GST-PDCD4.  In this 
context, PDCD4 interacted with V5-eIF4AIII but at a low level (Figure 2.3, lane 1).  To 
our surprise, PDCD4 reproducibly interacted with V5-eIF4AIIIP67L to a greater extent 
than to wild-type (Figure 2.3, lane 2 versus 1).  This indicates that there may be 
interacting partners of wild-type eIF4AIII that inhibit PDCD4 binding while eIF4AIIIP67L 
has lost these interactions allowing for residual binding of PDCD4. eIF4AIII is known to 
bind Y14 and MAGO tightly in the context of the EJC.  It would be interesting if 
eIF4AIIIP67L has lost the ability to interact with these proteins.     
To further characterize conditions that alter PDCD4/eIF4AIII binding, I 




tested for interaction with endogenous PDCD4 in a cell lysate context.  GST-eIF4AIII did 
not interact with endogenous PDCD4 under two different buffer conditions (Figure 2.4, 
lane 1 and 4) in contrast to robust interaction with GST-eIF4AII (Figure 2.4, lanes 2 and 
5).   
The inability of eIF4AIII to interact with endogenous PDCD4 indicates that 
binding partners or posttranslational modification of PDCD4 may inhibit this interaction.  
PDCD4 levels, and potentially binding partners and post-translational modifications, 
could be altered under cell stress conditions or at different cell cycle phases.  The ability 
of eIF4AIII to interact with endogenous PDCD4 could also be enhanced under different 
cell growth conditions.   To further determine if changes in cell growth conditions 
influence GST-eIF4AIII binding to PDCD4, lysates from serum starved or mitotically 
enriched cells were prepared.  Purified eIF4AIII failed to recover endogenous PDCD4 
under any of these conditions (Figure 2.5, lane 1).  To verify the results that eIF4AIIIP67L 
interacts with PDCD4 to a greater extent in the cell lysate context, it would be interesting 
to see if purified GST-eIF4AIIIP67L associates with endogenous PDCD4 in cell lysates.  
It is interesting that PDCD4 can bind to eIF4AIII when both are recombinant but 
is unable to interact using material from transformed cells.  Partnerships taking place in 
the cell could be interfering with binding.  Alternatively, the ability of PDCD4 to interact 
with eIF4AIII could be changed by post-translational alterations, such as methylation, 
sumoylation, and phosphorylation, that do not occur when these proteins are expressed in 
prokaryotes.  Protein partners or posttranslational modifications could be altered by the 
cell cycle, transformed status, or the differentiated state of a cell.  Although my studies 




eIF4AIII, it remains interesting to consider whether disruption of, or forced interaction 
between PDCD4 and eIF4AIII, alters EJC-dependent aspects of mRNA biogenesis and 
contributes to a pro-tumor growth phenotype.   
 
2.4.2 Recombinant PDCD4 interacts with Nup153 and Nup62 
Data from a yeast two-hybrid screen performed by Prolexys indicated that 
PDCD4 interacts with a number of nuclear pore complex proteins.   To validate these 
findings, purified GST-PDCD4 was immobilized on glutathione resin and incubated in 
Xenopus egg extract.  Enriched proteins were eluted and separated by PAGE and 
immunoblots probed for nuclear pore proteins using the 414 monoclonal antibody that 
recognizes multiple Nups. Both Nup153 and Nup62 were enriched with GST-PDCD4 
while Nup214 was not (Figure 2.6, lanes 1).  In an attempt to find negative binding 
controls, we probed pull-downs for Nup98, β-COP and Tubulin.  β-COP and Tubulin 
showed a positive interaction with PDCD4 whereas Nup98 turned out to be a good 
negative control (Figure 2.7, lane 1).  We also tested ARF1 and α-COP, both of which 
did not interact (data not shown).  To determine if PDCD4 interacts with Nup153 and 
Nup62 from mammalian cells, GST-PDCD4 was immobilized on glutathione resin and 
incubated in HEK293 cell lysates.   Nup153 interacted with PDCD4 whereas Nup62 did 
not (Figure 2.8, top panel, lane 1).  As in Xenopus extract, Nup98 from mammalian cells 
did not interact with PDCD4 (Figure 8, middle panel, lane 1).  We have yet to confirm if 
Tubulin and  β-COP bind to PDCD4 in mammalian cell lysates.   
The ability to interact with the translation initiation complex and bind to RNA 




initiation factors are thought to be loaded onto mRNAs in the nucleus for the pioneer 
round of translation and may be transported to the cytoplasm through the nuclear pore 
complex (23, 24).  The efficiency of these mRNPs to transit between subcellular 
compartments is an important step in efficient translation since polyribosome loading 
occurs in the cytoplasm.   It is interesting, in this light, that a translation inhibitor, 
PDCD4, interacts with nuclear pore components Nup153 and possibly Nup62.  In non-
cancerous cells, PDCD4 is often found primarily in the nucleus (6, 8, 9).  PDCD4 may 
dock at the nuclear pore in the context of mRNPs and travel transiently to the cytoplasm 
to inhibit translation of susceptible mRNAs.  It is also possible that PDCD4 functions as a 
molecule that sorts transiting mRNPs, inhibiting or facilitating the export of mRNA-
protein complexes.  PDCD4 could also negatively impact translation by forcing the 
retention of mRNAs in nucleus.  It would be interesting to determine if the subcellular 
localization of a class of mRNAs, such as those with specific sequences or structures, was 
altered in PDCD4 overexpressing cells by assessing mRNAs from nuclear and 
cytoplasmic cell fractions by microarray.      
   
2.4.3 PDCD4 binds proteins differentially in interphase  
versus mitotic egg extract 
Overexpression of nondegradable PDCD4 causes delays in G1-S phase transition 
(25) and altering the levels of PDCD4 causes changes in p21waf1/cip1 expression (26).  It is 
unclear exactly what role PDCD4 plays during the cell cycle but its ability to act as a 
tumor suppressor may be due, in part, to a role in cell cycle control perhaps independent 




differentially during alternate phases of the cell cycle could illuminate novel roles 
PDCD4 plays during the cell cycle.  Toward this end, I probed interphase versus mitotic 
Xenopus egg extract for novel interacting partners of PDCD4.  
 GST-PDCD4 was immobilized on glutathione resin and incubated with either 
interphase or mitotic egg extracts.  Interacting proteins were separated by PAGE and 
were visualized by Coomassie staining.  We found two prominent bands that bound 
exclusively to interphase or mitotic extracts.   The first band of interest was at 72 kD and 
appeared only when interphase extract was used (Figure 2.9 lane 1), whereas a 30kD 
band was observed only with mitotic material (Figure 2.9, lane 2).  Neither 72 kD or 30 
kD band bound to GST (Figure 2.9, lanes 3-4).  These bands were excised and processed 
for mass spectrometry analysis.   
I was particularly interested in the number of ribosomal subunits that were 
identified in the mitotic egg extract (Table 2.1).  To follow up on this line of experiments, 
isolation of ribosomes out of mitotic egg extracts was performed using GST-PDCD4, but 
with variable results.  A recent paper describes an interaction between PDCD4 and the 
ribosomes confirming these mass spectrometry results (27).   Further experimentation is 
needed to determine which of these subunits interact with PDCD4 and whether this is 
bridged by mRNA and/or the eIF4F complex.  Furthermore, determining if a PDCD4 
interaction with ribosomes is cell cycle regulated in mammalian cells is of interest.   
The first two proteins identified in the interphase extract were two alleles of 
protein arginine methyltransferase 5 (PRMT5) (Table 2.2).  In humans, there is only one 
allele while Xenopus laevis expresses both xPRMT5 (a hypothetical protein that I have 




nomenclature).  This interaction is explored in greater detail in the following section and 
Chapter 3 (see Figure 3.3).     
 
2.4.4 PRMT5 differentially binds to PDCD4 in interphase  
versus mitotic Xenopus egg extract 
Analysis of the 72 kD protein in the interphase extract by mass spectrometry 
yielded mostly peptides from the protein PRMT5, also known as Hsl7.  I confirmed that 
PDCD4 binds to PRMT5 in interphase egg extract by immunoblot (Figure 2.10,  lane 1).  
To rule out that changes of buffer conditions between interphase and mitotic extracts 
contributed to PRMT5 binding to PDCD4, cyclin B was added to shift interphase extract 
into a mitotic state.  The cell cycle state of the egg extract was confirmed by monitoring 
hyperphosphorylation of Nup153 in mitotic extract versus hypophosphorylation in 
interphase state with resulting molecular weight shift (Figure 2.11 bottom panel lanes 1-
7).  With addition of cyclin B, PRMT5 no longer interacted with PDCD4 (Figure 2.11, 
top panel, lane 7).  To further determine substantiate this cell cycle binding preference, 
CSF egg extract (CSF is an egg extract that has been arrested in mitosis by cytostatic 
factor) was used.  CSF extract progresses from mitosis to interphase if phosphatase 
inhibitors (PI) are omitted.  In CSF treated with PI, GST-PDCD4 bound to PRMT5 to a 
much lower extent (Figure 2.11 lanes 2 and 4), comparable to regular mitotic extract or 
interphase extract with the addition of cyclinB (Figure 2.11, lanes 6-7).  When CSF was 
allowed to cycle out of a mitotic state, GST-PDCD4 was able to interact with PRMT5 at 




2.11, lane 5) showing that this interaction is preferential in Xenopus egg extract only in 
the interphase but not mitotic state.    
To determine if similar cell cycle regulation of the PDCD4-PRMT5 partnership 
occurs in mammalian cells, unsynchronized lysate and lysates enriched in prometaphase 
by nocodazole treatment were incubated with recombinant PDCD4.  Interacting proteins 
were separated by PAGE and interrogated for PRMT5 by immunoblotting.   PRMT5 
bound equally as well in asynchronous and mitotic enriched lysates from both HEK293 
and HT29 cells (Figure 2.12, lanes 1-4).  The mitotic state of the lysates was assessed by 
phospho-histone H3 levels (Figure 2.12, lanes 9-12).    
The ability of PDCD4 to interact with PRMT5 only in interphase but not mitotic 
Xenopus laevis egg extract indicates that this interaction may be cell cycle regulated 
within this context.  This regulation does not appear to happen in mammalian cells tested.   
This indicates the lack of such regulation in transformed tissue culture cells, but does not 
rule it out in normal mammalian cells.  Furthermore, the Xenopus egg extract represents 
an early undifferentiated cell environment, leaving open the question of whether PDCD4 
and PRMT5 are regulated in development (both frog and mammalian).  It would be 
interesting to determine whether mis-regulation of PDCD4 and PRMT5 interaction has a 
developmental phenotype.  
 
2.5 Discussion 
Discovery of new PDCD4 interacting factors indicates the possibility that PDCD4 
plays multiple roles in the cell.  These roles could be complementary or independent of 




proteins all have roles in RNA biogenesis.  eIF4AIII is a critical component of the exon 
junction complex that regulates mRNA  stability and transit to the cytoplasm from the 
nucleus.  If PDCD4 interacts with cellular eIF4AIII it could regulate either of these 
functions.  The ability of PDCD4 to bind to Nup153 and possibly Nup62 may connect 
PDCD4 to the site of mRNA trafficking, the nuclear pore complex.  This could indicate a 
sorting function or a jumping off point for PDCD4 as it transits to the cytoplasm to 
presumably function in translation regulation.  Finally, the ability of PDCD4 to bind to 
PRMT5 points to a potential modulatory role in stable spliceosome assembly since 
PRMT5 is a methyltransferase that targets Sm proteins to enhance their incorporation into 
snRNPS (28, 29).    The interaction of PDCD4 with PRMT5 will be explored further in 
Chapter 3.   
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Figure 2.1  eIF4AIII and II share conserved amino acids known to contact PDCD4.  
Alignment of eIF4AIII with the known PDCD4 interacting partner eIF4AII shows greater 
than 60% identity.  Asterisks represent identical amino acids.  Amino acids known to directly 
be involved with PDCD4 binding are shown in red type with the surrounding conserved 
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Figure 2.2  Recombinant PDCD4 and eIF4AIII interact in vitro in a manner 
dependent on proline 67 of eIF4AIII.  Purified His-tagged recombinant PDCD4 interacts 
with purified GST-tagged recombinant eIF4AIII (top panel, lane 1).  The eIF4AIIIP67L 
mutant has reduced binding to PDCD4 (top panel, lane 3).  His-tagged tandem GFP was 
used as a negative control (top panel, lanes 2, 4, 6, and 8).  Recombinant GST-tagged 
eIF4AII interacts with His-PDCD4 (top panel, lane 5).  Recovery of GST-tagged proteins 
was tracked by immunoblotting with GST-specific antibody (bottom panel, lanes 1-8). 
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Figure 2.3 GST-PDCD4 recovers eIF4AIIIP61L to a greater extent than wild-type 
eIF4AIII from cell lysates.  Lysates from HEK293 cells transfected with V5-tagged 
eIF4AIII, V5-eIF4AIIIP67L, or parental vector (see Input, top panel, lanes 7-9) were 
incubated with purified GST-PDCD4.  Input and bound material was subjected to 
immunoblotting to detect V5-tagged proteins (upper panel) and the membrane was 
subsequently stained with Coomassie to assess GST recovery (bottom panel). Wild-type 
eIF4AIII associated to a lower extent than eIF4AIIIP67L with GST-PDCD4 (top panel, lane 

















































Figure 2.4 GST-eIF4AIII is unable to interact with endogenous PDCD4 from cell 
lysates. Purified GST-eIF4AIII cannot interact with endogenous PDCD4 from HEK293 
lysates (top panel, lane 1).  GST-eIF4AII efficiently pulls down endogenous PDCD4 from 
HEK293 lysates (top panel, lane 2).  GST recombinant proteins were visualized by 
subsequent Coomassie staining of the immunoblot (bottom panel, lanes 1-6).    The binding 
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Figure 2.5 Changing cell growth status does not stimulate interactions between 
PDCD4 and recombinant eIF4AIII.  GST-eIF4AIII does not interact with endogenous 
PDCD4 from lysates of HeLa cells grown under normal culture conditions (top 
immunoblot, lane 1) or  serum starved (middle immunoblot, lane 1) or  treated with 
nocodazole to trap in mitosis (bottom immunoblot, lane 1).  GST-eIF4II interacted with 
PDCD4 under all cell culture interactions (all immunoblots, lane 2).  Recovery of GST 
recombinant proteins for all conditions were visualized by subsequent Coomassie staining 
of immunoblot membranes (see three Coomassie panels).   Lysates loaded at 10% of 











































Figure 2.6  GST-PDCD4 interacts with Nup153 and Nup62 in ultra-S egg extracts. 
Purified GST-PDCD4 or GST was incubated with Xenopus ultra-S egg extract and 
interacting proteins were separated by PAGE and probed for Nups using the 414 antibody.  
PDCD4 interacts with Nup153 and Nup62 but not Nup214 (lane 1).  Loading controls were 
visualized by Coomassie staining of a gel with 1 ug of GST-PDCD4 or GST loaded (lanes 
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Figure 2.7  GST-PDCD4 interacts with β-COP and Tubulin, but not with Nup98. 
Purified GST-PDCD4 or GST was incubated with Xenopus egg extract and interacting 
proteins were separated by PAGE and probed for interacting partners by immunoblotting.  
PDCD4 fails to interact with Nup98 (top panel, lane 1) but does interact with β-COP 
(middle panel, lane 1) and Tubulin (bottom panel, lane 1).  Loading controls were 




































Figure 2.8  GST-PDCD4 interacts with Nup153 but not Nup62 or Nup98 in HEK293 
cell lysates. Purified GST-PDCD4 was incubated with HEK293 lysates and interacting 
proteins were separated by PAGE and probed for interacting partners by immunoblotting 
with mAb414.  PDCD4 interacts with Nup153 but not Nup62 in mammalian cell lysates 
(top panel, lane 1).  PDCD4 fails to interact with Nup98 (middle panel, lane 1).  Recovery 
of GST-PDCD4 was visualized by subsequent Coomassie staining of immunoblot (bottom 
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Figure 2.9  Differential binding partners of GST-PDCD4 in interphase and mitotic 
Xenopus egg extract. GST-PDCD4 was incubated with interphase or mitotic Xenopus egg 
extract and interacting proteins were separated by PAGE visualized by Coomassie 
staining.  A specific 72 kD protein interacted with PDCD4 in interphase extracts and was 
excised for mass spec analysis (lane 1, bracket).  A 30 kD species interacted with PDCD4 
in mitotic egg extract and was also excised and subjected to mass spec analysis (lane 2, 
bracket).  Asterisk indicates GST-PDCD4 band.  Part of this gel was used in Figure 3.2 , 
Chapter 3 (Powers et al., submitted).
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Figure 2.10  PRMT5 interacts with PDCD4 in Xenopus egg extract and this 
interaction is cell cycle regulated. Purified GST-PDCD4 was incubated with interphase 
and mitotic Xenopus egg extract and interacting proteins were separated by PAGE.  
Interacting species were detected by immunoblot using PRMT5 antibody (top panel) and 
by silver staining (bottom panel).  The mass spec indentified interaction of PRMT5 with 
PDCD4 was confirmed (top panel, lane 1) and this interaction was more robust in 
interphase than mitotic egg extract (top panel, lane 1 versus lane 2).  Arrow shows robust 
72 kD band by silver stain in interphase egg extract (bottom panel, lane 1).  
63
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Figure 2.11  Mitotic state, not buffer conditions, regulates interaction of PDCD4 with 
PRMT5. GST-PDCD4 was incubated in two different preparations of CSF Xenopus egg 
extract either without (lanes 1 and 3) or with phosphatase inhibitors (lanes 2 and 4).  
PDCD4 interacts to a greater extent with PRMT5 in CSF egg extract in an interphase state 
(top panel, lanes 1 and 3) than in a mitotic state maintained with inhibitors (top panel, lanes 
2 and 4).  These interactions are comparable to that seen in normal interphase and mitotic 
egg extracts (top panel, lanes 5 and 6).   Interphase extract incubated with cyclinB to induce 
transition to mitotic state has lowered PRMT5 binding than interphase extract alone (lane 
7 versus 5).  Recovery of GST-PDCD4 loading was visualized by subsequent Coomassie 
staining of immunoblot membrane (middle panel, lanes 1-7).  Interphase and mitotic state 
of extracts was assessed by immunoblot with mAb414 to detect hypophosphorylation of 
Nup214 and Nup153 (interphase state, bottom panel, lanes 1, 3, and 5) versus 
hyperphosphorylation (mitotic state, bottom panel, lanes 2, 4, 6-7).  Input levels of PRMT5 
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Figure 2.12  PDCD4 binds to PRMT5 equally well in asynchronous and prometaphase 
enriched human cell lysates.  GST-PDCD4 was incubated in asynchronous and 
nocodazole treated lysates from HEK293 (lanes 1-2) or HT29 (lanes 3-4) cells. PRMT5 is 
efficiently recovered with GST-PDCD4 from all lysates and cell cycle conditions (top 
panel, lanes 1-4).  The mitotic state of the lysates was assessed using phospho-histone 3 
antibody (middle panel, lanes 9-12). PRMT5 did not interact with GST alone (top panel, 
lanes 5-8). Recovery of GST-PDCD4 and GST was visualized by subsequent Coomassie 





Table 2.1 Mitotic interacting partners of PDCD4 identified by mass spectrometry  
   
(Run- 








40S ribosomal protein S4/ 
40S ribosomal protein S4, 
X isoform 
Q6NRW9 29.6 627 Belongs to the ribosomal protein S4E family. 
(1-9) 
 
40S ribosomal protein 
S3a/ 40S ribosomal 
protein S3? 




ribosomal protein SA Q7ZX07 33.9 202 Small ribosomal subunit 
(1-13) 
 
60S acidic ribosomal 
protein P0/ 60S acidic 
ribosomal protein P0 
 
Q8AVI3 34.1 124 Ribosomal protein 
(1-15) 
(2-9) 
Rps6-prov protein/ 40S 
ribosomal protein S6 Q7ZYU0 28.7 73 Ribosomal subunit 
(1-16) 
(2-14) 
Rps2e protein/  Ribosomal 
protein S2 Q7T0R9 30.2 72 
Belongs to the ribosomal 
protein S5P family 
(1-29) 
 
MGC80804 protein/ 40S 
ribosomal protein S9 
Q5XHQ8 
Q6GNX6 22.6 21 
Belongs to the ribosomal 
protein S4P family 






protein) / ADP/ATP 
translocase 3 
Q9I9M9 32.9 684 






ADP/ATP translocase 1 Q6IP28 33.1 404 









Q6INH3 33.6 111 



































Cytochrome P450, family 
1, subfamily A, 
polypeptide 1 variant 
[Fragment] 













kinase catalytic subunit 
alpha-1 
Q5U5E3 64 24 Belongs to the Ser/Thr protein kinase family. 
Miscellaneous 
(1-1) 
(2-2) vitellogenin A2 precursor/? S03124 201.4 1234 
Precursor-product 
relationship between 
vitellogenin and the 
yolk proteins as derived 
from the complete 
sequence of a Xenopus 
vitellogenin gene 
(1-6) 





Ns:zf-e326 protein/  SPRY 
domain-containing SOCS 
box protein 1 
Q7ZX62 30.8 45 






binding protein-like 3/ 
Guanine nucleotide-
binding protein-like 3 
Q7ZX41 60.8 30 GTP binding/regulation of cell proliferation 
(1-28) 
 
MGC82350 protein/ CDK5 
regulatory subunit-
associated protein 3 
Q6AZH9 57.5 22 Regulator of CDK5 activity 
(2-15) 






8 ? 36 ? 
(2-17) 
 
Proteasome subunit alpha 
type/ Proteasome subunit 
alpha type-4 




Table 2.1 continued  
(Run- 











homeobox-like protein 1 
O73867 41.8 28 DNA binding transcription factor 
(2-19) 
 
MGC69081 protein/ VEZT 
protein Q6PCG6 88.3 25 ? 
(2-20) 



















Myosin head domain 
containing 1 variant 
[Fragment] 
Q569U0 11 20 Myosin complex 
(2-24) 
 
Sister chromatid cohesion 
protein PDS5 homolog A-
B/ Sister chromatid 
cohesion protein PDS5 
homolog A 







3 115 19 






complex subunit 2 
Q5PQ00 45.5 19 DNA binding/ Part of the SNAPc 
(2-27) 
 
Ambp protein/ AMBP 
protein [Precursor] Q7SZ46 38.5 18 






Table 2.2 Interphase interacting partners of PDCD4 identified by mass spectrometry 
   










Hsl7 protein/ Protein 
arginine N-methyltransferase 
5 











inner membrane protein 
Q3KQ64 54.6 21 Mitochondrion inner membrane protein 
RNA metabolsim 
8 MGC85069 protein/ Pre-mRNA-splicing factor 18 Q5EAV6 39.7 39 RNA splicing 
13 
MGC114630 / CDNA 
FLJ10005 fis, clone 
HEMBA1000156. 
[Fragment] 
Q498L2 11.3 29 RNA binding 
17 
LOC446275 protein / Serine-
arginine repetitive matrix 
protein 2 




Thioredoxin reductase 3 
[Fragment] 










Q7ZXD7 83.3 22 Procollagen-lysine 5-dioxygenase activity 






Table 2.2 continued 
 
 
Rank Name Xenopus/Human Accession # MW kD Peptide Hits Known Function 








MGC53952 protein/ Heat 
shock cognate 71 kDa 
protein 
Q7ZTK6 70.7 304 





XlZPA protein/ Zona 
pellucida sperm-binding 
protein 2  




related protein 7  
Q6DJE9 32.9 29 
Signal transduction 

















subunit alpha-5  










Q2TAQ7 21.7 22 ER to Golgi vesicle-mediated transporter 









PRMT5 ACCELERATES TUMOR GROWTH BY ARGININE METHYLATION OF 
THE TUMOR SUPPRESSOR PDCD4 
 
3.1 Abstract 
Programmed Cell Death 4 (PDCD4) has been described as a tumor suppressor, 
with high expression correlating with better outcomes in a number of cancer types. Yet, 
subpopulations of cancer patients, despite high PDCD4 expression in tumors, have poor 
survival, suggesting oncogenic pathways may inhibit or change PDCD4 function. Here, 
we explore the significance of PDCD4 in the context of breast cancer and describe the 
discovery of Arginine Methyl Transferase 5 (PRMT5) as a cofactor that radically alters 
PDCD4 function. Specifically, we find that co-expression of PDCD4 and PRMT5 in an 
___________________ 
 
This chapter is a modified version of a paper submitted to Cancer Research.  This 
paper was co-first authored by Matthew A. Powers and Marta M. Fay.  The following 
authors are Rachel E. Factor, Alana L. Welm and Katharine S. Ullman.  Author 
contributions:  MP: discovered interaction between PDCD4-PRMT5, oversaw truncation 
mutations of PDCD4, developed MCF7e cell lines and measured and analyzed tumor 
growth in mice and helped analyze clinical breast cancer data, wrote paper; MF: 
discovered PDCD4 methylation and performed all methylation reactions and discovered 
methylation site arginine 110 and made all methyl-mutants, analyzed data, edited 
paper;RF: assessed protein expression in clinical samples; AW: designed research and 
analyzed data, edited paper; KU: designed research and analyzed data; wrote paper. 
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orthotopic model of breast cancer causes accelerated tumor growth and that this growth 
phenotype is dependent on both the catalytic activity of PRMT5 and a site of 
methylationwithin the N-terminal region of PDCD4.  In agreement with the xenograft 
model, elevated phenotype is dependent on both the catalytic activity of PRMT5 and a 
site of methylation within the N-terminal region of PDCD4.  In agreement with the 
xenograft model, elevated PRMT5 expression correlates significantly with worse 
outcome within the cohort of breast cancer patients whose tumors contain higher levels of 
PDCD4. These results reveal a new cofactor for PDCD4 that alters tumor suppressor 
function and point to the utility of PDCD4/PRMT5 status as both a prognostic biomarker 




Although an active area of research where significant advances have been 
achieved, breast cancer is a leading cause of mortality among women (2). Breast cancer is 
a heterogeneous disease that can be difficult to stratify into distinct categories with 
precise outcomes, especially as improved detection methods allow for diagnosis of early 
subclinical disease (3). The dilemma of unknown/unquantifiable risk assessments can 
lead to over-treatment, accompanied by unwanted side effects, or under-treatment, which 
risks increased recurrence (4). Increasingly, biomarkers, such as hormone receptors, are 
used to enhance outcome predictions and refine treatment plans. Expanding the arsenal of 
prognostic biomarkers will help reduce guesswork in treatment plans, leading to better 
overall survival and improved quality of life.  
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Programmed Cell Death 4 (PDCD4) is a promising biomarker that correlates with 
better outcomes in lung, colon, ovarian and esophageal cancer (5-8). PDCD4 is expressed 
at lower levels in invasive breast carcinoma compared with ductal carcinoma in situ or 
normal samples, indicating there may be loss of PDCD4 during disease progression (9). 
Experimental models substantiate a tumor suppressor role for PDCD4. In a mouse 
epithelial cell line, PDCD4 expression reduced phorbol ester-induced transformation (10) 
and, in transformed cells, PDCD4 expression suppressed anchorage-independent cell 
growth (11). Transgenic mice expressing epidermal PDCD4 were resistant to chemically 
induced skin tumors (12), while PDCD4 knockout mice developed B-cell lymphoma 
(13).  
Here, we find that PDCD4 expression in breast cancer correlates with better 
survival. Yet, as with many biomarkers, there are limitations in using PDCD4 to predict 
outcome: subsets of patients whose tumors contain elevated PDCD4 mRNA still 
experienced poor clinical outcome, indicating the presence of mechanisms that abrogate 
or change PDCD4 function. Pursuing such a mechanism, we have found a novel PDCD4-
interacting partner, PRMT5, which posttranslationally methylates PDCD4. Together, 
these proteins cause a pro-growth tumor phenotype in an orthotopic breast cancer model. 
Moreover, we have found that PRMT5 is a significant factor in determining long term 
survival in PDCD4-upregulated breast cancer. Discovery of this new pro-tumor growth 
pathway improves the utility of PDCD4 as a prognostic tool and reveals PRMT5 as a 
potential therapeutic target, whose inhibition may unmask the function of a tumor 




3.3 Experimental Procedures 
3.3.1 Constructs 
 Open reading frames for human PDCD4, PRMT5 and the PDCD4 truncation 
mutants were PCR cloned with Gateway (Invitrogen) compatible ends and introduced 
into pDONR221. PRMT5cd was created by mutation of amino acids glycine 367 and 
arginine 368 to alanines (14). The pGEX-4T vector and the pMIG (Addgene plasmid 
9044, William Hahn) vector were made Gateway compatible using the RFB and RFA 
oligos (Invitrogen) respectively. PDCD4, PDCD4 point mutants and truncation mutants 
were cloned into the pGEX-4T Gateway compatible vector. PRMT5 and PRMT5cd were 
cloned into the pcDNA3.1 nV5/DEST (Invitrogen). PDCD4 and PDCD4mm were cloned 
into the pMIG Gateway compatible vectors, while PRMT5 and PRMT5cd were cloned 
into pMSCVpuro (Clontech) vector using BglII and EcoRI cut sites.    
 
3.3.2 Recombinant protein production 
Cultures of BL21/RIL cells (Novagen) transduced with PDCD4-pGEX4T were 
induced using 0.1mM IPTG for 1-3 hours.  Pellets were resuspended and sonicated in 
1xPBS, 0.4mM PMSF, 5µg/ml leupeptin and aprotinin, 5% deoxycholate. Cleared 
supernatants were incubated with glutathione beads followed by TBS wash and elution in 
100mM Tris pH 8.0, 150mM NaCl, 20mM glutathione. Purified protein was dialyzed into 






3.3.3 Recombinant PDCD4 pull downs in human cell lysates 
Ten µg of GST-proteins were incubated with glutathione resin (GE Healthcare) in 
binding buffer (20 mM Hepes pH7.6, 100 mM KCl, 0.5 mM EDTA, 0.25% Triton X-
100, 20% glycerol) at room temperature for 1 hour. GST-glutathione conjugates were 
washed and incubated with 100-300 µg of cell lysate in a final volume of 200 µl binding 
buffer for 1 hour at room temperature. Proteins were eluted in SDS sample buffer 98°C 
for 3 minutes.  
 
3.3.4 Preparation of ecotropic retrovirus and MCF7e infections 
To prepare virus, HEK293T cells were cotransfected with pCL-Eco plasmid and 
pMIG or pMSCVpuro retroviral vectors in a 1:3 ratio. One day after transfection, the 
medium was exchanged with fresh media. Virus containing medium was collected 48 
hours after transfection and filtered through a 0.45 micron filter. Virus was diluted 1:4 
into MCF7 media (DME:F12 1:1, 10% FBS, 10 mg/L insulin) and mixed with polybrene 
(to 8 µg/ml) . This virus mixture was overlaid on 20-50% confluent MCF7e cells, which 
stably express an ecotropic receptor. Virus media was exchanged for MCF7 media at 24 
hours. Cells were maintained for ~1 week prior to selection. pMIG-transduced cells were 
selected by FACS for GFP-positive cells and pMSCVpuro-transduced cells were selected 
for 2 weeks with 2 µg/ml puromycin.    
 
3.3.5 Transplantation of transduced MCF7e cells and tumor growth 
One-million cells were diluted into 10 µL of matrigel (BD bioscience) and kept 
on ice. Three-week-old recipient NOD/SCID mice were anesthetized with vaporized 
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isoflurane and then injected with the cell suspension into the cleared inguinal fat pads as 
described (15). Tumors were physically measured using calipers at 14-21 day intervals 
throughout duration of growth. Mice were sacrificed by CO2 asphyxiation and visible 
tumors collected.  Upon sacrifice of mice, lungs, spleen and liver were dissected and 
visually inspected for macro-metastases. Micro-metastases were assessed by detection of 
GFP positive cells in tissues using an Olympus MVX10 dissecting scope with a UV light 
source.   
 
3.3.6 V5-Immunoprecipitation 
HEK293 cells were transiently transfected with catalytically active or dead 
PRMT5 pcDNA3.1 nV5/EXP vectors. Cells were lysed in methylation buffer (1mM 
DTT, 0.25% Triton X-100, 5% glycerol in 1 x PBS) 18-24 hours after transfection and 
incubated with V5 antibody (Invitrogen) conjugated to protein A beads. One mg of lysate 
was incubated with prebound beads for a minimum of 2 hours at 4ºC. IPs were washed 
three times with methylation buffer prior to use in further reactions 
 
3.3.7 Methyltransferase reactions 
One to five µg of GST tagged protein was incubated with HEK293 cell lysate or 
immunoprecipitated V5-PRMT5 in methyl buffer and supplemented with 0.5-2 μCi 3H-
SAM (Perkin Elmer). Reactions were incubated at 30°C for 1 hour and terminated by 
addition of SDS sample buffer. Tritiated proteins were separated by SDS-PAGE, and 
transferred to PVDF. For autoradiography, blots were treated with Enhance Spray (Perkin 
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Elmer) according to manufacturer’s recommendations and exposed to film at -80°C for 6 
hours-5 days.  
 
3.3.8 Antibodies 
PDCD4 and PRMT5 antibodies were acquired from Abcam. For immunoblots, α-
PDCD4 antibody was used at 1:2000 while α-PRMT5 antibody was used at 1:1000 and 
cell lysates were loaded at 2.5-5 µg per lane.  Anti-V5 antibody (2F11F7 Invitrogen) was 
used at 1:1000, anti-tubulin (YL1/2, Accurate chemical and Scientific Corp.) at 1:2000 
and anti-β-actin (AC-74, Sigma) at 1:2000 for immunoblots.  
 
3.3.9 Gene expression and statistical analysis 
Gene expression and clinical outcome information were obtained from two 
independent publicly available datasets (1, 16, 17). Clinical outcomes from the Pawitan 
study (17) was obtained from data published in the Ivshina study (1). Data for PRMT5 
and PDCD4 were extracted from normalized expression data for each breast tumor 
sample, and patients were divided into groups based on expression of the two genes. Each 
dataset was analyzed separately. For the data from the van de Vijver study, distant 
metastasis was analyzed as first event only. If a patient developed a local recurrence, 
axillary recurrence, contra-lateral breast cancer, or a second primary cancer (except for 
non-melanoma skin cancer), she was censored at that time. Any distant metastasis after 
the first event was not analyzed, based on the theoretical possibility that the secondary 
cancers could be a source for distant metastases. An ipsalateral supra-clavicular 
recurrence was considered as first clinical evidence for metastatic disease for this 
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analysis. Therefore, patients with ipsalateral supra-clavicular recurrence were not 
censored. Patients were censored at last follow-up. Kaplan-Meier survival curves were 
generated using the software WINSTAT FOR EXCEL (R. Fitch Software, Staufen, 
Germany), and p values were calculated by log-rank analysis. p values <0.05 were 
considered significant. 
All tissue samples used for this study were obtained from informed and consented 
patients under an approved IRB protocol.  All animal experiments were reviewed and 
approved by the U of U IACUC prior to conducting the experiments. 
 
3.4 Results 
3.4.1 Analysis of PDCD4 as a prognostic marker in breast cancer 
To determine the relationship between PDCD4 transcript expression in breast 
cancer and patient survival, we evaluated a previously published microarray dataset. This 
dataset was obtained from tumors less than 5cm deposited at the Netherlands Cancer 
Institute from 295 breast cancer patients under the age of 55 (16). We stratified this 
dataset into two groups based on PDCD4 transcript levels, with the “high” group 
representing those above the median. High expression significantly correlated with better 
probability of survival (p=0.0014) (Figure 3.1). Nevertheless, a significant fraction of 
patients within the high PDCD4 cohort (~35%, which extrapolates to over 38,000 new 
patients this year in the U.S. alone (2)) did not appear to gain benefit from this elevated 
expression. One explanation for this could be the presence of interacting partners of 






3.4.2 A novel interaction between PDCD4 and PRMT5 
To look for potential new regulatory factors of PDCD4, we took a biochemical 
approach to identify binding partners. We used Xenopus laevis egg extract, which has the 
advantage of limited manipulation to disrupt protein complexes and retains a very high 
concentration of proteins. A 72 kD protein was consistently recovered from egg extract 
with recombinant PDCD4 (Figure 3.2A). When analyzed by mass spectrometry, this 
protein was identified as Protein Arginine Methyltransferase 5 (Figure 3.3). To confirm 
that PDCD4 also interacts with human PRMT5, lysates were made from HEK293 and 
three breast cancer cell lines, and interacting proteins were similarly isolated using GST-
PDCD4, this time on an analytical scale. Immunoblotting the proteins retained with 
recombinant PDCD4 confirmed the interaction with human PRMT5 and indicated that 
this is an interaction to consider in the context of breast cancer (Figure 3.2B). 
PRMT5 is a type II methyltransferase and catalyzes addition of a methyl group to 
both terminal nitrogens of arginine residues (18). Like other posttranslational 
modifications, methylation can alter protein function, localization and/or binding partners 
(18). To assess whether PRMT5 has the potential to be a regulatory factor in the context 
of breast cancer, we examined a set of clinical biopsies for protein expression. This 
survey found that PRMT5 is expressed in breast cancer and can vary in level as well as 
whether it is co-expressed with PDCD4 (Figure 3.4).  
 
3.4.3 PDCD4 and PRMT5 synergistically enhance tumor growth 
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Over-expression of PRMT5 transforms NIH3T3 cells and has been found to be 
upregulated in leukemia, lymphoma and gastric cancer (14, 19, 20).  The presence of 
PRMT5 in breast cancer, its potential to modulate protein activity, and its reported 
attributes as a pro-tumor factor prompted us to test whether PRMT5 influences the role of 
PDCD4 in a tumor context. To do so, MCF7 breast cancer cells were engineered to 
express elevated levels of either protein alone or in concert. PDCD4 and PRMT5 
expression levels were confirmed by immunoblot analysis (Figure 3.5A). There were no 
gross phenotypic changes as a result of increased expression of these proteins and all four 
cell lines had similar doubling times under normal tissue culture conditions (Figure 
3.5B).  
To assess tumor growth, cells were transplanted orthotopically into NOD/SCID 
mice. Increasing levels of either PDCD4 or PRMT5 alone in the context of MCF7e cells  
did not significantly alter the growth rate of the tumor (Figure 3.5C). However, the 
PDCD4-PRMT5 co-expressing cells exhibited significantly faster growth as tumors than 
singly-expressing PDCD4, PRMT5 or control cell lines (Figure 3.5C). 
Immunohistochemical analysis of harvested tumors showed the expected elevated levels  
of PDCD4 and PRMT5 expression (Figure 3.6). Analysis of lungs, spleen, and liver 
showed no significant difference in metastasis between cell lines. 
 
3.4.4 PDCD4 is methylated in the N-terminal domain at R110  
and is a target of PRMT5 
To determine if PDCD4 can be methylated and possible regions of modification, 
we fragmented PDCD4 into two domains. We noted that the N-terminal region contains 
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an arginine rich (RR) subdomain (Figure 3.7A). The second region contains the MA3 
domains responsible for eIF4A binding (Figure 3.7A) (21-23). Purified GST-fusion 
proteins of full-length and both truncation mutants were incubated with cell lysate as an 
enzyme source and supplemented with tritiated S-adenosylmethionine (SAM) as the 
methyl donor.  Only full-length protein and the N-terminal fragment were labeled (Figure 
3.7B). To further map the methylation site of PDCD4, we took a candidate approach. 
Within the arginine-rich region of PDCD4, R73 and R110 are flanked by glycines, 
resembling canonical methylation sites (Figure 3.7A). These arginines were mutated to 
lysine, conserving the amino acid charge but disrupting potential methyl acceptor sites. 
Mutation of R73 had no effect, whereas mutation of R110 abolished methylation (Figure 
3.7C, lanes 2 and 4). Arginine 110 is therefore the major methyl acceptor site within 
PDCD4. 
To determine if PRMT5 itself methylates PDCD4, wild-type or catalytically dead 
PRMT5 (PRMT5cd) were transiently expressed and then immuno-isolated (Figure 3.7D). 
These enzyme sources were incubated with purified GST-PDCD4 and 3H-SAM. Labeled 
GST-PDCD4 was detected in reactions using wild-type PRMT5 (Figure 3.7D, lane 4), 
demonstrating that PDCD4 can be targeted for methylation by PRMT5. PDCD4 was  
labeled at greatly reduced levels in reactions using PRMT5cd; this residual activity is 
likely due to the ability of mutant PRMT5 to homo-oligomerize with its endogenous 
counterpart (24).  Mutation of R110 again resulted in the absence of methylation (Figure 
3.7D, lane 7), confirming that this is the acceptor site for methylation by PRMT5.   
  
3.4.5 The catalytic activity of PRMT5 and PDCD4-R110  
are necessary for enhanced tumor growth 
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The ability of PRMT5 to function as a pro-cancer factor in leukemia/lymphoma 
cells is dependent on its methyltransferase activity (20). However, PRMT5 overrides a 
G2/M phase checkpoint independent of enzymatic activity (25). To determine if PRMT5 
enzymatic activity is necessary to promote tumor growth in our breast cancer model 
system, MCF7e cell lines were generated expressing PRMT5cd alone or in conjunction 
with wild-type PDCD4 (Figure 3.8A). These cells were transplanted orthotopically and 
assessed for tumor growth over a 22 week period. As controls, vector only and wild-type 
PDCD4-PRMT5 cells were also re-transplanted. The new injection of the PDCD4-
PRMT5 cell line tracked well with the previous PDCD4-PRMT5 tumor growth rate, 
underscoring their synergistic effect (Figure 3.8B). However, the PRMT5cd-PDCD4 cells 
did not show an accelerated growth rate (Figure 3.8B, C), indicating that the enzymatic 
activity of PRMT5 is necessary for enhanced tumor growth due to co-expression with 
PDCD4.  
To determine whether PDCD4 is the relevant target of PRMT5 in this context or 
whether PRMT5 is working through a parallel pathway. MCF7e cell lines were generated 
expressing the methyl mutant PDCD4mm (PDCD4 with R110K mutation) with or without 
wild type PRMT5 and then assessed for tumor growth (Figure 3.8A). Tumor growth of 
PDCD4mm with PRMT5 was not significantly different from the control cell line (Figure 
3.8C). This indicates that methylation of PDCD4, and R110 in particular, is necessary for 
the enhanced tumor growth observed with co-expression of both wild type PDCD4 and 
PRMT5.  
 
3.4.6 Clinical data indicate that PRMT5 levels impact the probability of  
survival when tumors express PDCD4 
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Our observations that simultaneous expression of elevated PDCD4 and PRMT5 
causes accelerated tumor growth in an orthotopic mouse model raised the question of 
whether this combination of markers would be useful in a clinical setting. To address this, 
we stratified patients with high tumor levels of PDCD4 into quartiles based on PRMT5 
expression. Each one of these cohorts can be extrapolated to approximately 25,000 
patients a year in the U.S. alone (2). We found that the top quartile –in which tumors 
highly express both PDCD4 and PRMT5– had poor outcomes, similar to the low PDCD4 
cohort. In contrast, with decreases in PRMT5 expression, the probability of survival 
increased significantly (p=0.0016)  The bottom quartile –high for PDCD4 and low for 
PRMT5– had remarkably better outcome than the top quartile (Figure 3.9A), with a 20-
year survival of 80% vs 43%. Similar quartile analysis of PRMT5 alone showed a trend in  
improved probability of survival with decreasing PRMT5, but was not significant (Figure 
3.9B). This suggests that the combination of PRMT5 and PDCD4 as biomarkers for 
outcome is potentially useful: high levels of PDCD4 are protective, unless PRMT5 is also 
highly expressed.   
To test the reproducibility of these observations, we used another, independent 
breast cancer dataset (1). We selected patients from this cohort based on availability of  
both clinical follow-up and gene expression data. This resulted in a set of 224 tumors, 
which we then stratified for PDCD4 expression, with “high” defined as those in the top 
third of expression levels. Patients in this high expression group also had a significantly 
higher probability of longer disease-free survival (p= 0.0066) (Figure 3.10A). Yet, within 
the high PDCD4 expression group there was still a >25% probability of relapse. We then 
further stratified the PDCD4 high group by PRMT5 levels (each sub-group extrapolates 
84 
 
to greater than 15,000 patients a year in the U.S. alone (2)) and, again, lower levels of 
PRMT5 proved to correspond to better outcome in this context (p=0.0203; Figure 3.10B), 
whereas quartile analysis of PRMT5 alone did not show a correspondence to outcome 
(Figure 3.10C). This data confirms that considering PRMT5 levels in the context of 




PDCD4 shows promise as a biomarker, with prognostic attributes in a number of 
cancers (5-8). Here, we further find that PDCD4 expression is informative with regard to 
survival of breast cancer patients, where increased levels correlate with better outcome in 
two large scale clinical evaluations.  PDCD4 expression alone, however, has limitations 
in stratifying cancer patient outcomes as ~30% of patients with tumors expressing 
relatively high PDCD4 mRNA levels have poor survival. This could be due to a potential 
discrepancy between mRNA and protein levels (26, 27), to environmental factors, or to 
interacting regulatory pathways.  
The discovery here of PRMT5 as an interacting partner opened a new level of 
regulation to consider. Neither PDCD4 nor PRMT5 affected tumor cell growth when 
expressed alone in our model system. Although this was somewhat surprising, it may 
indicate that in a particularly aggressive or advanced tumor context, elevated expression 
of either protein alone is insufficient to alter tumor properties. In the case of PDCD4, this 
may be due at least in part to endogenous levels of PRMT5. Importantly, the orthotopic 
tumor model revealed that, together, elevated PDCD4 and PRMT5 expression 
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significantly enhanced tumor growth. This result suggests that PRMT5 does not just 
negate a PDCD4 tumor suppressor function, but works synergistically to promote tumor 
growth. This pro-growth effect occurred only in the tumor context, not in tissue culture, 
hinting that the combination of proteins activates a pathway that enhances the ability to 
establish a productive tumor microenvironment. A dual role for a tumor suppressor as a 
contributor to oncogenesis is not unprecedented. For instance, p27 is considered a tumor 
suppressor via blocking cyclin activation, but has cyclin-independent roles that promote 
oncogenesis (28).    
 The change in PDCD4 function that occurs in the presence of elevated PRMT5 
pointed to a role for post-translational modification. We found that indeed PDCD4 is 
methylated and is a target of PRMT5 at R110. Furthermore, the PDCD4 methyl mutant 
expressed with wild type PRMT5 or the catalytically dead PRMT5 expressed with wild 
type PDCD4 failed to promote tumor growth. This demonstrates that methylation of 
PDCD4 by PRMT5 is critical for enhanced tumor growth. The methylation target residue, 
R110, lies near a S6 Kinase 1 site (S67) reported to regulate PDCD4 stability (27, 29). 
While levels of ectopic expression of PDCD4 did not appear to be influenced by the 
presence of PRMT5 or mutation of R110 (Figure 3.5 and 3.8), whether there is cross-talk 
between these post-translational modifications requires further investigation.    
PDCD4 is thought to exert its tumor suppressor role by regulating translation (21, 
30), fitting with a growing theme of translation initiation as a node of regulation in cancer 
(31).  More specifically, the ability of PDCD4 to function as an inhibitor of 
transformation and anchorage-independent cell growth relies on its ability to bind to the 
translation initiation factor eIF4A (21, 30, 32). Interestingly, PRMT5 has been shown to 
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influence eIF4E levels (33) and was recently shown to interact with the ribosomal subunit 
RPS10 and, through methylation, influence ribosomal stability (34). Although 
methylation of PDCD4 may impact its role in translation regulation, we cannot rule out 
that, conversely, methylated PDCD4 changes PRMT5 function or specificity. In addition 
to the recent connection to translation, PRMT5 is known to be involved in transcription 
(14, 20, 35), in efficient assembly of the spliceosome (36), and in modulation of  p53-
dependent cell cycle arrest (33, 37). Methylated PDCD4 could interact with PRMT5 and 
accelerate tumor growth by altering these or other functions downstream of PRMT5 (33, 
37).  
By integrating biochemical and tumor model data, we have found that an elevated 
level of PRMT5 in conjunction with PDCD4 reverses the tumor suppressive properties of 
PDCD4. Chemical inhibition of PRMT5 methyltransferase activity could abrogate the 
synergism between PDCD4 and PRMT5, potentially unmasking PDCD4 tumor 
suppressor function in cancers that express both proteins. The finding that combined 
expression analysis of PDCD4 and PRMT5 is a powerful prognostic indicator for 
outcome in breast cancer suggests that these factors could be used as rational, activity-
based biomarkers to aide in decisions about how aggressively to treat a breast cancer 
patient. Finally, although our focus here has been on breast cancer, PDCD4 plays a tumor 
suppressor role in a wide spectrum of cancers (5-7), raising the possibility that its 
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Figure 3.1 Analysis of PDCD4 as a prognostic marker in breast cancer. Microarray 
data from 295 tumors less than 5 cm collected from patients younger than 55 and stored at 
the Netherlands Cancer Institute (13) was analyzed with respect to PDCD4 expression. 
Patients with tumors expressing PDCD4 mRNA above the median (“high”, shown in blue) 






















































Figure 3.2 PRMT5 is a protein partner of PDCD4. (A) Coomassie-stained gel of 
proteins associated with GST-PDCD4 (lane 1; GST-PDCD4 indicated with arrowhead), 
compared to background levels of proteins that associate with GST (lane 2), following 
incubation with Xenopus laevis egg extract. The gel was sliced (bracket), to recover a 72 
kD band. Analysis by mass spectrometry identified PRMT5 in this gel slice. (B) Upper 
panel: immunoblot to detect PRMT5 among proteins associated with GST-PDCD4 (lane 2) 
or GST (lane 3), following incubation with lysates from the human cell lines indicated. 
8.5-17% of input material is shown in lane 1.  Lower panel: Coomassie stain of western 
blot (DU-4475 samples), showing recovery of GST-tagged proteins (lanes 2, 3).
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R.SYTIG.L, K.VYAVEK.N, K.QPISLR.E, K.GFPVLSK.V, K.GFPVLTK.V, K.LYNEVR.A, K.TDSEVSR.I, K.LYNEVR.A, R.WLGEPIK.A, 
R.SDLLLSGR.D, R.VPLLAHNDLR.D, R.SDLLLSGR.D, K.SRPGPQTR.S, R.GPLVNASLR.A, K.IKVYAVEK.N, R.EFYKEPAK.S, 
K.QEDNSNLSR.L, R.VPLMAPNDLR.D, K.REFYKEPAK.S, K.YSQYQQAVYK.C, R.TWIWWHNFR.S, K.NPNAVITLEGWR.Y
K.AAFLPTSIFLTNKK.G, K.AAFLPTSLFLTNKK.G, K.ETNIQVLMVLGAGR.G, K.LSDWIQTDSEVPQTR.K, K.DKDPEAQFEMPYVVR.L
R.VALAIEVGADLPSGHVIDR.W, R.YEEWGSQVTVVSGDMR.E, K.DRDPEAQFEMPYVVR.L, K.IALAIEIGADLPSGHVIDR.W,
R.EKDRDPEAQFEMPYVVR.L, R.EKDKDPEAQFEMPYVVR.L, K.EDGVSIPGEYTSFLAPISSSK.L, K.DDGVSIPGEYTSYLAPISSSK.L
R.LLINHILSGHHSTMFWMR.V, R.VPEEEKETNIQILMVLGAGR.G, R.VPEEEKETNIQVLMVLGAGR.G, 
K.GYEDYLQSPLQPLMDNLESQTYEVFEKDPVK.Y 
B xPRMT5   1 MAAGGGGRVSSGRDLGCVTEVADTLGAVAKQGFDFLCMPIFHPRFKREFYKEPAKSRPGP xHsl7    1 MAAGDGGRVSSGRDVACVTEVADTLGAMANQGFDFLCMPIFHPRFKREFYKEPAKSRPGP 
           **** *********  *********** * ****************************** 
 
xPRMT5  61 QTRSDLLLSGRDWNTLIVGKLSDWIQTDSEVPQTRKTSEAALQQELHFSAYLGLPAFLIP 
xHsl7   61 QTRSDLLLSGRDWNTLIVGKLSDWIKTDSEVSRIRKTSEAAMQQELNFSAYLGLPAFLIP 
           ************************* *****   ******* **** ************* 
 
xPRMT5 121 LKQEDNSNLSRLLINHILSGHHSTMFWMRVPLLAHNDLRDDLIENEPFSPSEEDNSGEER 
xHsl7  121 LKQEDNSNLSRLLINHIHVGHHSTMFWMRVPLMAPNDLRDDLIENEPISLSEEDNSGEER 
           *****************  ************* * ************ * ********** 
 
xPRMT5 181 TWIWWHNFRSLCDYNKRVALAIEVGADLPSGHVIDRWLGEPIKAAFLPTSLFLTNKKGFP 
xHsl7  181 TWIWWHNFRSLCDYNKKIALAIEIGADLPSGHVIDRWLGEPIKAAFLPTSIFLTNKKGFP 
           ****************  ***** ************************** ********* 
 
xPRMT5 241 VLSKVHQRLIFRLFKLEVQFVISGAHHHSEKDFCSYLQYLEYLSQNRPPPNAYEMFAKGY 
xHsl7  241 VLTKVHQRLIFKLFKLEVQFVISGSHHHSEKDLCSYLQYLEYLSQNSPPPNAYEMFAKGY 
           ** ******** ************ ******* ************* ************* 
 
xPRMT5 301 EDYLQSPLQPLMDNLESQTYEVFEKDPVKYSQYQQAVYKCLLDRVPEEEKETNIQVLMVL 
xHsl7  301 EDYLQSPLQPLMDNLESQTYEVFEKDPVKYSQYQQAVYKCLLDRVPEEEKETNIQILMVL 
           ******************************************************* **** 
 
xPRMT5 361 GAGRGPLVNASLRAAKQAERKIKVYAVEKNPNAVITLEGWRYEEWGSQVTVVSGDMREWK 
xHsl7  361 GAGRGPLVNASLRAAKQAERKIKVYAVEKNPNAVITLEGWRYEEWGSQVTVVSGDMREWK 
           ************************************************************ 
 
 
xPRMT5 421 APEKADIIVSELLGSFGDNELSPECLDGAQHFLKEDGVSIPGEYTSFLAPISSSKLYNEV 
xHsl7  421 APEKADIIVSELLGSFGDNELSPECLDGAQHFLKDDGVSIPGEYTSYLAPISSSKLYNEV 
           ********************************** *********** ************* 
 
xPRMT5 481 RACREKDKDPEAQFEMPYVVRLHNFHQLSDPLPCFTFHHPNKDAVIDNNRYCCLQYRVDL 
xHsl7  481 RACREKDRDPEAQFEMPYVVRLHNFHQLSDPLPCFTFHHPNKDDVIDNNRYCCLQYRVDL 
           ******* *********************************** **************** 
 
xPRMT5 541 NTVLHGFAGYFSTVLYKDVTLSICPESHSPGMFSWFPILFPIKQPISLREGDTVCVRFWR 
xHsl7  541 NTVLHGFAGYFNTVLYKDVTLSICPESHSPGMFSWFPILFPIKQPIPMREGDTVCVRFWR 
           *********** **********************************  ************ 
 
xPRMT5 601 CNNGKKVWYEWAVTSPVCSAIHNPTGRSYTIGL 
xHsl7  601 CNNGKKVWYEWAVTSPVCSAIHNPTGRSYTIGL 
           ********************************* 
Figure 3.3 72kD protein isolated with GST-PDCD4 from Xenopus egg extract 
corresponds to the two alleles of PRMT5 found in Xenopus. (A) List of peptides 
recovered from excised gel slice that correspond to Xenopus PRMT5.  (B) Alignment of 
identified peptides within amino acid sequence of the two alleles of PRMT5 found in 
Xenopus laevis. At top is theoretical protein xPRMT5 (Q2VPH9) with alignments in 
yellow and below is xHsl7 (Q6NUA1) with alignments in red. Green highlights specific 
sequences recovered that are unique to each allele, confirming the expression (and binding) 
of both proteins.  This demonstrates that the theoretical protein xPRMT5 is expressed.    
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Figure 3.4. Immunohistochemical survey of tumor biopsies.  (A) Invasive ductal 
carcinoma that is poorly differentiated with positive nuclear staining for both PDCD4 and 
PRMT5.  (B) Invasive ductal carcinoma with lymphovascular invasion.  PDCD4: 
Membranous positive staining in carcinoma and lymphovascular invasion. PRMT5: weak 
positive cytoplasmic blush. (C) Invasive ductal carcinoma. Both PDCD4 and PRMT5 
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Figure 3.5 Co-expression of PDCD4 and PRMT5 enhances tumor growth in 
xenograft model. (A) MCF7e cells expressing PDCD4 and PRMT5 or empty constructs, 
as indicated, were assessed by immunoblot. Tubulin levels were tracked as a loading 
control. (B) Cell growth in tissue culture was measured for 7 days by a colorimetric assay 
tracking the cleavage of WST substrate (BioVision) by cellular mitochondrial 
dehydrogenase. (C) The cell panel was transplanted orthotopically and tumor volume was 















Figure 3.6 Immunohistochemical evaluation of harvested tumors.  
Immunohistochemical analysis of PDCD4 (antibody 1:5000) and PRMT5 (antibody 
1:1000) expression in tumors recovered from mice (60x magnification). Expression 
constructs for each sample are listed at top. Panel at right is the no primary control.
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Figure 3.7 PDCD4 can be methylated in its N-terminal domain and is a target of 
PRMT5.  (A) Schematic of PDCD4, with arginine rich (RR) region and MA3 regions 
indicated.  Amino acids 1-156 are shown, with the RR region underlined. (B) Upper panel: 
autoradiograph of reactions containing purified GST-PDCD4 (lane 1) or domain fragments 
(lanes 2, 3) along with HEK293 cell lysate and 3H-SAM. Middle panel: immunoblot for 
tubulin, tracking lysate level in methylation reactions. Bottom panel: total protein in each 
reaction detected by Coomassie staining; * indicate recombinant protein present in each 
reaction. (C) Arg110 and/or Arg73 were mutated to lysines in full length PDCD4 or the 
N-terminal region (aa1-156), as indicated. These proteins, and wild-type (WT) 
counterparts, were incubated with cell lysates supplemented with 3H-SAM. Top panel: 
samples were subjected to PAGE followed by autoradiography. Middle panel: immunoblot 
to detect GST fusion proteins. Lower panel: immunoblot for tubulin, to track levels of cell 
lysate used. (D) V5-PRMT5, the catalytically dead mutant (V5-PRMT5cd), or control 
vector were transiently expressed and then cell lysates subjected to immunoprecipitation 
with anti-V5 antibody. Left panels are immunoblots of precipitated material using PRMT5 
antibody (upper panel) or V5 antibody (lower panel). GST-PDCD4 (lanes 4-6) or 
GST-PDCD4R110K (lanes 7-9) were incubated with immunoprecipitates shown in lanes 1-3 
along with 3H-SAM.  Methylation was monitored by autoradiography (upper panel). The 


























































































































































































































































Figure 3.8 The catalytic activity of PRMT5 and arginine 110 of PDCD4 are necessary 
for synergistic tumor cell growth. (A) Immunoblot of MCF7e cells expressing R110K 
(methyl mutant) PDCD4mm and PRMT5cd with wild type PRMT5 or PDCD4 as indicated. 
(B) Tumor growth of PDCD4mm-PRMT5 and PDCD4-PRMT5cd cell-lines is graphed along 
with repeats (-2) of vector only and PDCD4-PRMT5. Data from the first tumor growth 
experiment with these two cell-lines (Figure 3) is shown for comparison. Vector-2 and 
PDCD4-PRMT5-2 tumors were generated by injection of cells into both cleared inguinal 
fat pads of 2 mice (n=4 tumors for each cell line). One mouse injected with the 
PDCD4-PRMT5 cell line died at week 4 causing an n=2 tumors (ϑ). These tumors tracked 
well with previous PDCD4-PRMT5 tumor growth rate, although the number was too low 








































































Figure 3.9 Expression of PRMT5, in conjunction with PDCD4, improves prediction 
of survival. mRNA expression data from the Netherlands Cancer Institute dataset (13) was 
analyzed with respect to both PDCD4 and PRMT5. (A) The “high” PDCD4 cohort of 
patients (see Figure 1) were stratified into quartiles based on PRMT5 expression, with the 
first quartile containing the highest levels of PRMT5 expression. (B) Patients from the 







































































Figure 3.10 An independent dataset confirms the prognostic power of a combined 
PRMT5/PDCD4 expression signature. Analysis of a second dataset of mRNA collected 
from the tumors of 224 patients from Singapore and Sweden (1) selected based on 
availability of clinical follow-up data and PDCD4 and PRMT5 expression. (A) This dataset 
was stratified into thirds based on PDCD4 expression levels.  Patients in the “high” 
expression cohort (top one-third) had greater probability of disease-free survival compared 
to all others. (B) The “high” PDCD4 cohort was further stratified into quartiles based on 
PRMT5 expression; less PRMT5 expression corresponded to increased probability of 
disease-free survival.  (C) Patients stratified into quartiles based on tumor expression of 












The ability of eIF4A to function as an RNA helicase is blocked when bound to 
PDCD4 resulting in the inhibition of efficient translation of mRNAs with structured 
5’UTRs.   The ability of PDCD4 to interact with eIF4A is dependent on the MA3 domain 
that is also found in other eIF4A binding proteins such as eIF4G.   Curiously, PDCD4 
contains two of these MA3 domains in tandem and it is unclear whether both MA3 
domains are necessary for eIF4A binding or if the most distal C-terminal domain is 
sufficient.  The studies described here demonstrate that both MA3 domains of PDCD4 
are necessary for efficient, direct binding to eIF4AII.  Furthermore, using RNA 
electrophoretic mobility shift assays, I found that PDCD4 inhibits the ability of eIF4AII 
to interact with RNA thereby inhibiting its RNA helicase activity.  This experimental 
strategy also allowed the RNA binding activity of PDCD4 to be tracked and revealed that 








PDCD4 was first characterized in a cancer context using a mouse epidermal cell 
model (1, 2).  Exogenous expression of PDCD4 inhibited transformation and also 
blocked tumor forming cells from efficient anchorage independent cell growth (2-4).  
These tumor suppressor properties were found to be dependent on the ability of PDCD4 
to bind the translation initiation factor 4A (eIF4A) (3).   In conjunction with suppressing 
tumor phenotypes, PDCD4 also downregulated translation of mRNAs that contained 
structure in the 5’untranslated region (5’UTR) by blocking the ability of eIF4AII to 
function as a RNA helicase.  The MA3 domain positioned closest to the C-terminus (the 
cMA3 domain) was found to be sufficient for translation inhibition in one study (5), 
while individual truncation mutations in either MA3 domain caused loss of translation 
inhibition in a second study (6).  This discrepancy prompted us to further characterize the 
mechanism required for PDCD4-mediated disruption of eIF4A activity.  
eIF4A is a component of a larger complex, eIF4F, that is instrumental in 
recruiting the ribosome to the start codon for translation initiation (7).  eIF4F is 
composed of three proteins, eIF4A, eIF4E and eIF4G.   eIF4E binds to the mRNA 
5’methyl cap, bringing the eIF4F complex to the 5’UTR of transcripts.  eIF4G is a large 
scaffold protein that links eIF4A to eIF4E.  In addition to holding together the eIF4F 
complex, eIF4G also links this complex to the 40S ribosomal subunit (7).  eIF4A has two 
isoforms in mammalian cells, eIF4AI and eIF4AII, that share 89% identity.  They are 
differentially expressed in various tissues and can each rescue the depletion of the other 
(8, 9).   eIF4AI or eIF4AII are often referred to as “eIF4A” when the known functions of 




by a process of conformational change catalyzed by ATP hydrolysis.  When ATP is 
bound, eIF4A binds tightly to RNA due to a high affinity RNA binding conformation.   
When ATP is hydrolyzed to ADP, eIF4A changes shape and releases RNA allowing for 
processive movement along the 5’UTR (10).   PDCD4 binds and blocks eIF4A RNA 
helicase function causing inefficient translation of mRNAs that contain structured 
5’UTRs (6), but it was unclear what mechanism PDCD4 uses to inhibit eIF4A helicase 
activity.   
More recently, eIF4A was recognized to be closely related to a different RNA 
helicase, eIF4AIII, that is a core component of the exon junction complex (11-13).  
Unlike eIF4A, eIF4AIII is not known to utilize its RNA helicase activity.  Instead, 
eIF4AIII is an anchor molecule that clamps down on RNA in its role as a core member of 
the exon junction complex.  This occurs through inhibition of eIF4AIII hydrolysis of 
ATP, locking it into a high affinity RNA binding state (14-16).  This inhibition is 
mediated by the EJC core components MAGOH and Y14 when they bind to eIF4AIII 
(17).  In an analogous manor, PDCD4 could bind to eIF4A and inhibit ATP hydrolysis 
thereby blocking RNA helicase activity.  Alternatively, PDCD4 could interact with 
eIF4A in a way that interferes with RNA binding, disrupting efficient translation 
initiation.  To distinguish between these possibilities, I tested the ability of eIF4AII to 
bind to RNA in the presence of PDCD4 and ATP or the non-hydrolyzable ATP analogue 
AMP-PNP.  I found that PDCD4 inhibits the ability of eIF4AII to interact with RNA 
thereby blocking its ability to function as an RNA helicase.  Furthermore, I found that 
both MA3 domains are necessary for efficient direct interactions between PDCD4 and 




bind RNA.  These results overlapped with those published by a different group while 
experiments were in progress (18).  While the approaches here followed a different 
strategy (see Discussion), the conclusions were similar and so we changed the emphasis 
of the project to what is described in Chapter 3. 
 
4.3 Experimental Procedures 
4.3.1 Constructs 
The PDCD4 open reading frame was purchased from Open Biosystems and 
eIF4AII open reading frame was cloned out of a human cDNA library.  PDCD4 and 
eIF4AII were introduced into pDONR221 vectors by BP reactions (Invitrogen).  
pGEX4T was made gateway compatible using RFB oligos (Invitrogen) and eIF4AII was 
cloned into this vector by LR reaction to produce GST-recombinant proteins.  To produce 
His-recombinant proteins, PDCD4 was cloned into pDEST-EXP1 by a LR reaction.   
 
4.3.2 Recombinant protein purification 
Recombinant proteins were expressed and purified as in section 2.3.2. 
 
4.3.3 RNA gel purification 
RNA oligos were run on a 12% acrylamide urea gel and the gel region where 
RNA migrates was excised (RNA migration was previously detected by ethidium 
bromide staining and successive  gels were assessed by loading dye migration).  Excised 
gel pieces were crushed using a pipet tip and RNA was allowed to elute from gel in 0.5 




were pelleted by low speed centrifugation and the supernatant was recovered.  The RNA 
was precipitated out of solution with the addition of glycogen (Ambion) and EtOH and 
was incubated at -80°C for 15 minutes.  RNA was pelleted by centrifugation at 20,000 x 
G for 30 minutes at 4°C.  Pellets were washed with 80% EtOH and resuspended in DEPC 
treated H2O.      
      
4.3.4 RNA probe labeling 
The 25 nucleotide hnRNP-A1 RNA binding site oligo was synthesized and gel 
purified.  One nMol of The RNA oligo was incubated with T4 polynucleotide kinase in 
the presence of γ 32P-ATP in kinase buffer (50 mM Tris pH 7.5, 10 mM MgCl2, 50 mM 
DTT) at 37°C for 1 hour. The labeling reaction was stopped by the the addition of EDTA 
to a final concentration of 1 mM.  RNA was precipitated with the addition of NaOAc, 
glycogen (Ambion) and EtOH.  Pellets were washed with 80% EtOH.  End labeling was 
checked by autoradiograph by running a portion of the sample on a denaturing urea gel 
and dehydrating onto Whatman paper.    
 
4.3.5 Gel shift assays 
Purified proteins were diluted 1:15 (approximately to 0.05 to 0.1 µg/µl) into gel 
shift salt buffer (25 mM HEPES pH 7.5, 100 mM KCl).  Approximately 0.1-0.4 µg of 
protein was added to 100 pMol of labeled RNA and diluted in 20 µl gel shift buffer (100 
mM KCl, 25 mM HEPES pH 7.5, 0.01% Triton X-100, 5% glycerol, 6 mM MgAOc, 0.3 
µg/µl BSA, 1 x protease inhibitors (Roche), 1 x RNAse out (Invitrogen), 0.2 µg/ul 




Reactions were terminated with the addition of native loading buffer.  Samples were run 
on 6% acrylamide native gels and dehydrated onto Whatman paper.  Gels were than 
subjected to autoradiograph.   
    
4.4 Results 
4.4.1 Both MA3 domains of PDCD4 are necessary for  
efficient eIF4A binding 
To determine exactly what domains of PDCD4 were necessary for efficient eIF4A 
binding, I engineered subfragments of PDCD4 (specifically, 2MA3 domain, the nMA3 
domain and the cMA3 domain, Figure 4.1) and expressed them as recombinant His-
tagged proteins.  eIF4AII was expressed as a recombinant GST-tagged protein and 
purified.  GST-eIF4AII and the His-tagged PDCD4 domains were incubated together.  A 
glutathione matrix was used to recover GST-eIF4AII and any interacting proteins were 
then separated by PAGE and immunoblotted with antibody directed against the 6-His tag.  
Full length PDCD4 and the 2MA3 domain  interacted with eIF4AII (Figure 4.2A, lane 3 
and Figure 4.2B, lane 1 and 3). The nMA3 and cMA3 domains did not interact with 
eIF4A (Figure 4.2A, lanes 1-2 and Figure 4.2B, lane 1).   His-tagged recombinant 
proteins did not interact significantly with GST alone (Figure 4.2A and B, lanes 4-6).     
 
4.4.2 PDCD4 blocks the ability of eIF4A to interact with RNA 
To understand mechanistically how PDCD4 blocks eIF4AII RNA helicase ability, 
I first purified both proteins (Figure 4.3 lanes 10-11).  To establish that recombinant 




was incubated with radiolabeled single-stranded RNA and ATP or the nonhydrolyzable 
analogue AMP-PNP.  This mixture was run on a non-denaturing acrylamide gel to 
separate free RNA from eIF4AII shifted species.  As expected, GST-eIF4AII efficiently 
shifted RNA in the presence of AMP-PNP but not with ATP (Figure 4.4, lanes 3-4).  
Inefficient RNA shifting in the presence of ATP indicates that GST-eIF4AII hydrolyzes 
ATP to ADP leaving eIF4AII in a low affinity RNA binding state.  Binding to AMP-PNP 
locked eIF4A into a high affinity RNA binding state allowing robust RNA:protein 
interaction, seen as a shifted species in this assay.  The specificity of the effect was 
confirmed by running a similar set of conditions with a control protein, hnRNP-A1. The 
ability of hnRNP-A1 to bind RNA was not perturbed by the addition of either ATP or 
AMP-PNP (Figure 4.4 lanes 5-6).   
To determine the effect on eIF4AII RNA binding in the presence of PDCD4, 
GST-eIF4AII was incubated with radiolabeled RNA and AMP-PNP with increasing 
amounts of His-PDCD4.  The addition of PDCD4 inhibited GST-eIF4AII from 
interacting with RNA (Figure 4.5, lanes 2-5).  PDCD4 also has intrinsic RNA binding 
ability and shifts RNA (Figure 4.5, lanes 3-5 and 10).  The lack of a super-shifted RNA 
species running at a different level than GST-eIF4AII indicates that a ternary complex of 
eIF4AII-PDCD4-RNA does not occur and, therefore, both PDCD4 and eIF4AII may 
block each other’s ability to bind RNA.   Addition of increasing amounts of His-PDCD4 
did not affect the ability of hnRNP-A1 to bind to RNA, showing that the inhibition of 
eIF4AII is specific (Figure 4.5, lanes 6-9).   
To test if eIF4AII blocks the ability of PDCD4 to interact with RNA, increasing 




nondenaturing gel revealed that His-PDCD4 binding is inhibited with the addition of  
GST-eIF4AII (Figure 4.6 lanes 2-5).  One caveat to this experiment is that there was 
RNA degradation with the addition of GST-eIF4AII with His-PDCD4, which may have 
skewed this result.  This is very likely the case in lane 5 where greater addition of GST-
eIF4AII does not correspond to a larger shifted band at the eIF4AII level indicating a 
reduced RNAs availability.  Nevertheless, lanes 3 and 4 appear to have intact RNA and 
shows a decrease in PDCD4 shifted species.  Together with a lack of super-shifted RNA 
species from Figure 4.4, this indicates that the ability of PDCD4 to bind RNA is inhibited 
by an interaction with eIF4AII.  Had I pursued this line of investigation, I would have 
purified the recombinant protein to a greater extent in order to eliminate the RNase and 
clarify the result. 
 
4.5 Discussion 
The interaction of PDCD4 with eIF4A is thought to be critical for PDCD4 tumor 
suppressor function (3, 6).  Determining how this interaction occurs, and how it 
modulates eIF4A function, is important in defining the effects of PDCD4 on oncogenesis.  
I have shown here that both MA3 domains within PDCD4 are necessary for efficient 
direct protein interaction with eIF4A.  This confirms a study that was published while I 
was performing these experiments (18).   In light of experiments where the transfection 
of the single cMA3 domain inhibited translation (5), however, the results of in vitro 
binding described here and by Suzuki et al (18) are surprising since individual MA3 
domains have low affinity for eIF4A.  This apparent discrepancy could result from 




exogenous expression forcing this interaction.  Alternatively, the cMA3 domain may 
have translation suppression properties apart from eIF4A.  Both scenarios need further 
investigation.   
These seemingly contradictory results from in vitro and cell-based assays 
highlight that alternative roles for PDCD4 in cancer and translation regulation may occur 
in vivo.    For example, post-translational modifications of PDCD4 or eIF4A may cause 
this complex to stimulate translation initiation rather than inhibiting it.  We have shown 
that the co-expression of PDCD4 with PRMT5 causes accelerated tumors growth in an 
orthotopic model (see Chapter 3).  This indicates that under these in vivo conditions 
PDCD4 becomes oncogenic.  Whether this change is due to a switch from being an 
inhibitor to an enhancer of translation enhancer would be an interesting problem to 
explore.   
The ability of PDCD4 to block eIF4A RNA helicase activity was also reported, 
when my experiments were in process, to occur through inhibiting the RNA binding 
activity of eIF4A.  Suzuki et al. took a different strategy, namely, an N-terminal 
truncation mutant of PDCD4 (missing the putative PDCD4 RNA binding site) was shown 
to displace U6 RNA from the N-terminal fragment of eIF4A by NMR experiments (18).  
I confirmed and extended these result by using full length PDCD4 and full length eIF4A 
in RNA gel shift analysis.  Furthermore, I have found that eIF4A may inhibit PDCD4 
RNA binding.  It has yet to be determined what role RNA binding plays in PDCD4 
cellular function but it is of increasing interest due to a recent report that found PDCD4 
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Figure 4.1 Schematic of PDCD4 showing nMA3 and cMA3 domains. The 2MA3 
domain extends from amino acids 157 to 469.  The nMA3 domain encompasses amino 
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Figure 4.2 Both MA3 domains on PDCD4 are necessary for efficient direct binding to 
eIF4AII. (A) GST-eIF4AII is able to interact with His-2MA3 (top panel, lane 3) but not the 
His-cMA3 or His-nMA3 domains (top panel, lanes 2-3).  GST-eIF4AII (bottom panel lanes 
1-3) and GST (bottom panel, lanes 4-5) were loaded equivalently and visualized by 
Coomassie staining of immunoblot.  Loading of His-nMA3 was low (top panel, lane 8) so 
a repeat of the experiment was performed using the 2MA3 and full length His-PDCD4 as 
controls. (B) GST-eIF4AII is able to interact with His-2MA3 (top panel, lane 1) and 
His-PDCD4 (top panel, lane 3) but not with His-nMA3 domain (top panel, lane 2).  Input 
levels of His-tagged proteins were similar (top panel, lanes 7-9).  GST-eIF4AII (bottom 
panel, lanes 1-3) and GST protein (bottom panel, lanes 4-6) were loaded similarly by 












































































Figure 4.3 Purification of His-PDCD4 and GST-eIF4AII proteins. His-tagged PDCD4 
(top panel) and GST-eIF4AII (lower panel) were expressed in BL21/RIL bacteria and, 
once fusion protein was captured on affinity matrix, the samples were extensively washed 
to reduce RNase contamination.  His-PDCD4 and GST-eIF4AII from the first elution (lane 
10) from nickel-NTA (top panel) and glutathione resin (lower panel), respectively, were 
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Figure 4.4 eIF4AII is locked onto RNA by addition of AMP-PNP.  GST-eIF4AII binds 
stably to labeled RNA in the presence of the non-hydrolyzable ATP analogue AMP-PNP 
(lane 3) better than in the presence of ATP (lane 4).  hnRNP-A1, which is insensitive to 
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Figure 4.5 PDCD4 blocks the ability of eIF4AII to interact with RNA.  GST-eIF4AII 
interacts with RNA in the presence AMP-PNP (lane 2).  Increasing additions of 
His-PDCD4 causes loss of eIF4AII binding to RNA (lanes 3-5) without the appearance of 
a higher molecular weight species indicating that PDCD4, eIF4AII, and RNA do not make 
a complex.  Increasing addition of His-PDCD4 does not inhibit hnRNP-A1 RNA binding 
(lanes 7-9), indicating that the PDCD4 induced inhibition of eIF4AII is specific.  PDCD4 
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Figure 4.6 Evidence that eIF4AII may inhibit PDCD4 binding to RNA.   His-PDCD4 
binds RNA (lane 2) and this binding is decreased with increasing amounts of GST-eIF4AII 
(lanes 3-5).  This experiment is not conclusive since there appears to be RNAse 
contamination (note alterations in free RNA, bottom bands lanes 3-5) when both PDCD4 










PDCD4 has been extensively studied in many types of in vitro assays for tumor 
suppression.  This has resulted in multiple anticancer mechanisms being attributed to 
PDCD4.  In vivo, PDCD4 knockout mice developed B-cell lymphoma.  This has lead to 
observations that expression of PDCD4 in tumors is correlated with longer survival 
and/or better outcomes in cancer patients.  Despite this, very few studies have directly 
tested in model organisms what has been discovered in vitro.  Many questions remain; 
does PDCD4 inhibit cancer through growth suppression, invasion inhibition or apoptosis 
stimulation, and what factors modulate these possible tumor suppressor functions in vivo?   
In Chapter 2, I describe new interacting partners of PDCD4: eIF4AIII, Nup153 
and PRMT5.  Interactions with these new proteins, along with eIF4G, eIF4AII, and 
ribosomes, places PDCD4 within the central framework of mRNA biogenesis from 
transcription through translation.  Possible regulation of splicing and mRNA transport 
from the nucleus to the cytoplasm points to new mechanisms of cell growth regulation for 
PDCD4 beyond translation.  Determining the role these interactions play in tumor 
suppression will involve separating the ability of PDCD4 to bind with each new partner 




Although I did not find a interaction between PDCD4 and the exon junction 
complex protein eIF4AIII using material from transformed tumor cell lines, this 
interaction could occur in normal cells or in other cancer contexts.  A PDCD4 interaction 
with the exon junction complex in normal cells could regulate mRNA fate, contributing 
to the repertoire of transcripts that maintain normal cell growth.  Disruption of this 
interaction in transformed cells may lead to enhanced potential for tumor growth.  The 
first priority to follow this lead would be to test whether an interaction between eIF4AIII 
and PDCD4 occurs in normal cells, such as the nontransformed MCF10A breast cell line.  
Detecting mRNA expression in PDCD4 knockout mice versus normal mice could be 
useful in determining changes in mRNA trafficking or stability.  Studies utilizing purified 
PDCD4 injected with intron-containing reporters into Xenopus egg nuclei could track any 
changes in mRNA fate directed by PDCD4.    
  The interaction with the nuclear pore protein Nup153 described in Chapter 2 
further underscores the possibility that PDCD4 may sort and/or traffic classes of mRNAs 
as they transit through the nuclear pore.  Changing the efficiency of mRNA transport 
from the nucleus to the cytoplasm would, by default, change the efficiency of translation 
as the polyribosome is loaded in the cytoplasm.  Determining classes of mRNAs that 
experience altered transit through the nuclear pore upon perturbation of PDCD4 may help 
classify proteins involved in tumor suppression or oncogenesis.  Nup153 also plays a 
novel role in mitotic control checkpoints (1).  Alterations of these noncanonical roles of 





 Although not confirmed in mammalian cancer cell lines, the regulation of 
PDCD4 and PRMT5 interaction in Xenopus is clearly cell cycle dependent (see Chapter 
2).  Many proteins are hyperphosphorylated during mitosis and the lack of binding 
between PDCD4 and PRMT5 in this cell phase points to a role of phosphorylation in 
controlling this interaction.  Determining what pathway is responsible for this binding 
inhibition, and promoting this pathway, may also block accelerated growth observed in 
tumors with high levels of PDCD4 and PRMT5.  A cell cycle regulated interaction 
between PDCD4 and PRMT5 was not observed in transformed human cells.  The 
difference observed between Xenopus egg extract and human cell lines could occur 
because of differences in differentiation, egg cells being embryonic and the human cell 
lines somatic, or could also be due to the human cells being transformed.  Alternatively, 
the discrepancy observed could be due to a difference in species regulation.  Determining 
the cell cycle regulation of PDCD4 and PRMT5 interaction in non-transformed human 
cells could help delineate if this discrepancy is due to misregulation in cancer or a species 
specific phenomena.           
The use of PDCD4 as a prognostic biomarker may encompass a broad swath of 
cancer types (see Chapter 1).  We have observed that elevated expression of PDCD4 
transcript in breast cancer tumors correlates with longer survival (Chapter 3).   This 
breast cancer analysis is very similar to observations in lung, colon and ovarian cancer 
where high levels of PDCD4 protein expression is correlated with longer survival (2-4).  
Despite these findings, in all cancer types, between 20 and 40% of patients with elevated 
tumor levels of PDCD4 have poor outcomes.   This suggests that mechanisms within 




discovery that PDCD4 interacts with PRMT5 provides one possible explanation for these 
observations.   In breast cancer tumors where both PDCD4 and PRMT5 mRNAs are 
upregulated, the protective effect of PDCD4 is clearly negated (Chapter 3).  This 
indicated that PRMT5 somehow deactivated PDCD4.  I tested how co-expression affects 
breast cancer growth in an orthotopic model and found the PDCD4 and PRMT5 work 
synergistically to promote tumor growth.  The enzymatic activity of PRMT5 and the site 
of PRMT5 modification on PDCD4 were both necessary for this accelerated tumor 
growth phenotype, providing a molecular mechanism for the correlations observed in 
clinical breast cancer data.  Originally, the PRMT5/PDCD4 interaction appeared to be 
simple case of an oncogenic factor deactivating a tumor suppressor by post- translational 
modification.  In effect, our theory was that the ratio of active oncogenic factors to tumor 
suppressors was tipped in the direction of tumor growth through this interaction.  Instead, 
neither PDCD4 nor PRMT5 expression alone resulted in changes in tumor growth.   
Rather, the PDCD4-PRMT5 overexpressing cells gained a new growth phenotype. This is 
one of the first examples of clinical correlations in the PDCD4 cancer biology field that 
was then tested in a model organism.  In the context of breast cancer, PDCD4 may have 
tumor suppressor properties when highly expressed but oncogenic functions when 
PRMT5 is also expressed.  This is not unprecedented.   The tumor suppressor p27 
function can also have oncogenic properties when post-translationally modified and 
cytoplasmically localized (5, 6).   This discovery also increases the accuracy of using 
PDCD4 as a predictive biomarker by pointing to the utility of tracking expression levels 
of PRMT5 at the same time.  Yet, we still do not know what biological effect is occurring 




The known PDCD4 tumor suppressor function results in inactivation of eIF4A 
and translation initiation.  Could methylation by PRMT5 cause a reversal of function for 
PDCD4 from a translation suppressor to a translation activator?  This is one possible 
scenario that will need to be explored.  Also, these results do not rule out that a complex 
of methylated PDCD4 and PRMT5 alters PRMT5 targets or enzymatic activity and 
thereby cause an accelerated tumor growth phenotype.  
PRMT5 belongs to the arginine methyl transferase (PRMT) family of enzymes.   
Type I PRMTs, such as PRMT1, mediates the addition of two methyl groups on one of 
the terminal nitrogens of arginine residues and this modification is termed an 
asymmetrical dimethylarginine (ADMA) (7).  PRMT5 belongs to the type II class of 
enzymes.  These enzymes catalyze the addition of a methyl groups onto both terminal 
nitrogens on an arginine residue and this modification is termed a symmetrical 
dimethylarginine (SDMA) (7).  PRMT5 is known to methylate Sm proteins for efficient 
assembly of snRNPs (8) and also modulates transcription (9-12).  Binding to the nuclear 
protein COPR5, PRMT5 is recruited to areas of the nucleosome and methylation of 
histone H4 leading to gene silencing of some targets (13).  When associated with 
SWI/SNF chromatin remodeling complex, PRMT5 is thought to methylate histone H3 
and H4 and also silence genes, notably, the tumor suppressors ST7 and NM23 (11).  In 
the case of myogenesis, association of PRMT5 with SWI/SNF can activate transcription 
(14).   PRMT5 also interacts with a transcription elongation factor hIws1 necessary for 
cell proliferation (15).  Overexpression of  PRMT5 can transform NH3T3 cells (11) and 
is highly expressed in some leukemia and lymphomas (10).  Finally, PRMT5 has been 




maintaining dedifferentiation in primordial germ cells (16, 17).   An association with 
PDCD4 could alter some, or all, of these function of PRMT5 and contribute to tumor 
growth.     
Finally, by RNA gel shift analysis, I describe the finding that PDCD4 interferes 
with the translation initiation protein, eIF4AII, by inhibiting its interaction with RNA 
(Chapter 4).  This is a clear mechanism by which PDCD4 interferes with the helicase 
function of eIF4A.   Furthermore, the intrinsic RNA binding function of PDCD4 appears 
blocked by binding to eIF4AII.  While this line of experiments were being performed, 
Suzuki et al. published a report where a truncated version of PDCD4 (not including the 
RNA binding domain) displaced RNA from the eIF4A N-terminal truncation mutant by 
NMR spectra analysis (18).  The RNA gel shift experiments here extend the findings of 
this result by using full length proteins and discovering that PDCD4 RNA interactions are 
also inhibited.   
PDCD4 shows promise as a useful biomarker in cancer.  In breast cancer, tracking 
PDCD4 and PRMT5 simultaneously increases the accuracy of prognosis based on these 
molecules.  Developing tools to track PDCD4 methylation status in cancer my further 
increase the value of this biomarker.  PRMT5 is a promising target for small molecule 
inhibitors due to its enzymatic activity and roles in oncogenesis.  Inhibition of PRMT5 
may well unleash the tumor suppressor function of PDCD4.  Determining what 
mechanism PDCD4 and PRMT5 utilize to increase tumor growth may also lead to new 
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